{"ticker": {"uuid": "6ac17112-224a-4034-ba52-6d46ce64f660", "symbol": "AZN", "name": "AstraZeneca PLC", "exchange": "BUE", "country": "AR", "sector": "Healthcare", "industry": "Drug Manufacturers - General"}, "articles": [{"title": "The Advertising Research Foundation Announces 2026 ARF David Ogilvy Awards Finalists", "summary": "NEW YORK, Aug. 13, 2026 /PRNewswire/ -- The Advertising Research Foundation (ARF) today announced the finalists for the 2026 ARF David Ogilvy Awards, honoring excellence in research-driven advertising and marketing. For more than 30 years, the ARF David Ogilvy Awards have recognized campaigns that demonstrate how consumer insights and research can inspire creative work that delivers measurable business results. This year's finalists represent leading brands across categories including Automotive, B2B, Cultural Fluency, Financial Services & Insurance, Food & Beverage, Health & Personal Care, Be", "url": "https://finance.yahoo.com/media-advertising/articles/advertising-research-foundation-announces-2026-150200996.html", "source_link": "https://finance.yahoo.com/media-advertising/articles/advertising-research-foundation-announces-2026-150200996.html", "source_link_is_lookup": false, "source_name": "finance.yahoo.com", "published_at": "2026-08-13T15:02:00+00:00", "published_display": "13 Aug 2026 15:02", "source_kind": "aggregator", "sentiment": "positive", "sentiment_pct": 59, "tone_signals": [], "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage", "is_stale": false, "evidence_weight": 0.068825, "evidence_share": 2.4, "evidence_share_display": "2.4", "freshness_pct": 98.9, "age_days": 0.1, "influence_label": "Low", "duplicate_count": 1, "topics": [], "evidence_basis": "", "score_included": true}, {"title": "Can Keytruda Sustain Merck's Growth in the Second Half of 2026?", "summary": "Merck's MRK strong foothold in the oncology space is backed by its biggest revenue driver, Keytruda. The blockbuster PD-L1 inhibitor alone accounts for more than 55% of the company's total pharmaceutical sales. In the United States, Keytruda is approved for 44 indications spanning 19 tumor types, along with two tumor-agnostic approvals as well as for many of these indications worldwide. Notably, more than 2,800 clinical studies are currently evaluating Keytruda across multiple cancer types and treatment settings. Keytruda, approved for several types of cancers, has played an instrumental role ", "url": "https://finance.yahoo.com/healthcare/articles/keytruda-sustain-mercks-growth-second-140000696.html", "source_link": "https://finance.yahoo.com/healthcare/articles/keytruda-sustain-mercks-growth-second-140000696.html", "source_link_is_lookup": false, "source_name": "finance.yahoo.com", "published_at": "2026-08-13T14:00:00+00:00", "published_display": "13 Aug 2026 14:00", "source_kind": "aggregator", "sentiment": "neutral", "sentiment_pct": 51, "tone_signals": ["Deteriorating financial comparison", "Operating deterioration", "Operating growth", "Positive market reaction"], "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage", "is_stale": false, "evidence_weight": 0.090644, "evidence_share": 3.2, "evidence_share_display": "3.2", "freshness_pct": 98.3, "age_days": 0.1, "influence_label": "Low", "duplicate_count": 1, "topics": ["Biosimilars", "Competition", "Earnings Per Share", "Immuno Oncology", "Oncology", "Patent Expiry"], "evidence_basis": "", "score_included": true}, {"title": "U.K. regulator reaffirms safety of childhood vaccination", "summary": "[Syringe drawing liquid medication from medical vial] zhikun sun/iStock via Getty Images Days after President Donald Trump ordered major changes to the U.S. childhood immunization schedule, the U.K. drug regulator on Wednesday reaffirmed the safety of pediatric vaccination, noting it remains one of the safest and most effective ways to fight many severe infectious diseases. Issuing an executive order to reduce the number of childhood vaccines administered in the U.S. and split the measles, mumps, and rubella vaccination into three separate shots on Monday, Trump suggested a link between vaccin", "url": "https://seekingalpha.com/news/4631498-uk-regulator-reaffirms-safety-of-childhood-vaccination?amp%3Butm_medium=referral&amp%3Bfeed_item_type=news", "source_link": "https://seekingalpha.com/news/4631498-uk-regulator-reaffirms-safety-of-childhood-vaccination?amp%3Butm_medium=referral&amp%3Bfeed_item_type=news", "source_link_is_lookup": false, "source_name": "seekingalpha.com", "published_at": "2026-08-12T13:13:40+00:00", "published_display": "12 Aug 2026 13:13", "source_kind": "publisher", "sentiment": "neutral", "sentiment_pct": 48, "tone_signals": ["Negative financial language"], "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage", "is_stale": false, "evidence_weight": 0.047106, "evidence_share": 1.7, "evidence_share_display": "1.7", "freshness_pct": 67.0, "age_days": 1.2, "influence_label": "Low", "duplicate_count": 3, "topics": ["Healthcare", "Regulation", "Split", "Vaccines"], "evidence_basis": "", "score_included": true}, {"title": "How AstraZeneca\u2019s $400bn deal unravelled", "summary": "One Broadway deal to start: Hollywood mogul Ari Emanuel has struck a roughly \u00a34.5bn deal to buy the theatre group behind West End venues including the Lyceum and the Savoy in a major bet that strong demand for live events is here to stay. In today's newsletter: AstraZeneca's Silver Upgrade to read this Financial Times article and get so much more. A Silver or Gold subscription plan is required to access premium news articles. Upgrade now", "url": "https://finance.yahoo.com/healthcare/articles/astrazeneca-400bn-deal-unravelled-040028643.html", "source_link": "https://finance.yahoo.com/healthcare/articles/astrazeneca-400bn-deal-unravelled-040028643.html", "source_link_is_lookup": false, "source_name": "finance.yahoo.com", "published_at": "2026-08-12T04:00:28+00:00", "published_display": "12 Aug 2026 04:00", "source_kind": "aggregator", "sentiment": "positive", "sentiment_pct": 76, "tone_signals": ["Operating growth"], "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage", "is_stale": false, "evidence_weight": 0.116265, "evidence_share": 4.1, "evidence_share_display": "4.1", "freshness_pct": 70.1, "age_days": 1.5, "influence_label": "Low", "duplicate_count": 3, "topics": [], "evidence_basis": "archived_article", "score_included": true}, {"title": "AstraZeneca PLC (AZN) vs. Bristol-Myers Squibb Company (BMY): Wall Street Doesn\u2019t Buy This Merger Talk", "summary": "AstraZeneca PLC (NYSE:AZN) shares closed down as much as 9% on Monday, the stock's biggest one-day drop since 2020, after reports that it held merger talks with U.S. rival Bristol-Myers Squibb Company (NYSE:BMY). A combined company would be worth close to $400 billion, the fourth-largest drugmaker in the world by market value. Neither firm confirmed the talks, and people familiar with the matter told Reuters a deal may never materialize. Why Investors Can't Figure Out the Logic Bristol Myers shares actually rose as much as 6% on the news before dropping back down a bit, a very different reacti", "url": "https://finance.yahoo.com/markets/stocks/articles/astrazeneca-plc-azn-vs-bristol-193445815.html", "source_link": "https://finance.yahoo.com/markets/stocks/articles/astrazeneca-plc-azn-vs-bristol-193445815.html", "source_link_is_lookup": false, "source_name": "finance.yahoo.com", "published_at": "2026-08-11T19:34:45+00:00", "published_display": "11 Aug 2026 19:34", "source_kind": "aggregator", "sentiment": "neutral", "sentiment_pct": 48, "tone_signals": ["Improving financial comparison", "Dilution risk", "Negative market reaction"], "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 85, "tier": "direct", "tier_label": "Direct company coverage", "is_stale": false, "evidence_weight": 0.104564, "evidence_share": 3.7, "evidence_share_display": "3.7", "freshness_pct": 82.9, "age_days": 1.9, "influence_label": "Low", "duplicate_count": 3, "topics": ["M A", "Oncology", "Patent Expiry", "Pharma", "Split"], "evidence_basis": "", "score_included": true}, {"title": "Do Options Traders Know Something About AstraZeneca Stock We Don't?", "summary": "Investors in AstraZeneca PLC AZN need to pay close attention to the stock based on moves in the options market lately. That is because the Jan. 15, 2027 $115.00 Call had some of the highest implied volatility of all equity options today. What is Implied Volatility? Implied volatility shows how much movement the market is expecting in the future. Options with high levels of implied volatility suggest that investors in the underlying stocks are expecting a big move in one direction or the other. It could also mean there is an event coming up soon that may cause a big rally or a huge sell-off. Ho", "url": "https://finance.yahoo.com/markets/options/articles/options-traders-know-something-astrazeneca-141100595.html", "source_link": "https://finance.yahoo.com/markets/options/articles/options-traders-know-something-astrazeneca-141100595.html", "source_link_is_lookup": false, "source_name": "finance.yahoo.com", "published_at": "2026-08-11T14:11:00+00:00", "published_display": "11 Aug 2026 14:11", "source_kind": "aggregator", "sentiment": "positive", "sentiment_pct": 69, "tone_signals": ["Improving financial comparison"], "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage", "is_stale": false, "evidence_weight": 0.053247, "evidence_share": 1.9, "evidence_share_display": "1.9", "freshness_pct": 48.0, "age_days": 2.1, "influence_label": "Low", "duplicate_count": 3, "topics": ["Biotech", "Implied Volatility", "Options Trading"], "evidence_basis": "", "score_included": true}, {"title": "Hedge Funds are Bullish on AstraZeneca PLC (AZN)", "summary": "AstraZeneca PLC (NYSE:AZN) topped second-quarter profit expectations, with core earnings per share of $2.63 versus the $2.48 analysts expected. The firm reiterated its target of $80 billion in annual revenue by 2030. However, the quarter also brought fresh pipeline trouble: its rare disease drug Ultomiris missed its main goal in a late-stage trial for a rare blood vessel complication in adults, the latest in a string of setbacks that also includes an earlier heart drug trial failure and a breast cancer drug application that U.S. regulators rejected. Why One Trial Miss Shook Confidence in the W", "url": "https://finance.yahoo.com/healthcare/articles/hedge-funds-bullish-astrazeneca-plc-140427321.html", "source_link": "https://finance.yahoo.com/healthcare/articles/hedge-funds-bullish-astrazeneca-plc-140427321.html", "source_link_is_lookup": false, "source_name": "finance.yahoo.com", "published_at": "2026-08-11T14:04:27+00:00", "published_display": "11 Aug 2026 14:04", "source_kind": "aggregator", "sentiment": "positive", "sentiment_pct": 67, "tone_signals": ["Beat expectations", "Deteriorating financial comparison", "Contract or approval won", "Operating growth"], "event_type": "earnings", "event_label": "Earnings", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage", "is_stale": false, "evidence_weight": 0.15831, "evidence_share": 5.6, "evidence_share_display": "5.6", "freshness_pct": 74.5, "age_days": 2.1, "influence_label": "Low", "duplicate_count": 3, "topics": ["Earnings", "Earnings Per Share", "Oncology", "Pharma", "Regulation", "Trials"], "evidence_basis": "", "score_included": true}, {"title": "MRK Stock Up 5.6% in a Month as Estimates Fall: Buy, Hold or Sell?", "summary": "Merck's MRK stock is up 5.6% in a month. The key reason for the increase was the strong second-quarter 2026 performance. Merck beat estimates for both earnings and sales in the second quarter. Revenues in the second quarter increased 5% to $16.61 billion as higher sales of oncology drugs, including Keytruda, and contributions from new products like Winrevair, Welireg, and Capvaxive, and the Animal Health segment were partially offset by lower sales of Gardasil and some other vaccines. Sales of blockbuster PD-L1 inhibitor Keytruda increased 4% to $8.4 billion. Merck also raised its 2026 revenue", "url": "https://finance.yahoo.com/markets/stocks/articles/mrk-stock-5-6-month-134800162.html", "source_link": "https://finance.yahoo.com/markets/stocks/articles/mrk-stock-5-6-month-134800162.html", "source_link_is_lookup": false, "source_name": "finance.yahoo.com", "published_at": "2026-08-11T13:48:00+00:00", "published_display": "11 Aug 2026 13:48", "source_kind": "aggregator", "sentiment": "positive", "sentiment_pct": 79, "tone_signals": ["Beat expectations", "Guidance raised", "Improving financial comparison", "Operating growth"], "event_type": "earnings", "event_label": "Earnings", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage", "is_stale": false, "evidence_weight": 0.206501, "evidence_share": 7.3, "evidence_share_display": "7.3", "freshness_pct": 74.4, "age_days": 2.1, "influence_label": "Low", "duplicate_count": 3, "topics": ["Acquisitions", "Earnings", "Oncology", "Patent Expiration", "Pharmaceuticals", "Revenue Growth"], "evidence_basis": "", "score_included": true}, {"title": "Polen International Equity adds NOK, MUFG; exits AIVAF, RNMBF among Q2 moves", "summary": "Polen International Equity Strategy outperformed the MSCI ACWI ex-US Index in the second quarter of 2026, returning 21.59% gross and 21.35% net of fees, respectively, versus 14.49% for the benchmark. During the quarter, the fund initiated new positions in ASPEED Technology, Ryohin Keikaku (RYKKF [https://seekingalpha.com/symbol/RYKKF]), Mitsubishi UFJ Financial Group (MUFG [https://seekingalpha.com/symbol/MUFG]), Tokio Marine Holdings (TKOMF [https://seekingalpha.com/symbol/TKOMF]), AstraZeneca (AZN [https://seekingalpha.com/symbol/AZN]), Nokia (NOK [https://seekingalpha.com/symbol/NOK]), Rent", "url": "https://seekingalpha.com/news/4630721-polen-international-equity-adds-nok-mufg-exits-aivaf-rnmbf-among-q2-moves?amp%3Butm_medium=referral&amp%3Bfeed_item_type=news", "source_link": "https://seekingalpha.com/news/4630721-polen-international-equity-adds-nok-mufg-exits-aivaf-rnmbf-among-q2-moves?amp%3Butm_medium=referral&amp%3Bfeed_item_type=news", "source_link_is_lookup": false, "source_name": "seekingalpha.com", "published_at": "2026-08-11T13:36:48+00:00", "published_display": "11 Aug 2026 13:36", "source_kind": "publisher", "sentiment": "positive", "sentiment_pct": 82, "tone_signals": ["Beat expectations", "Operating growth"], "event_type": "earnings", "event_label": "Earnings", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage", "is_stale": false, "evidence_weight": 0.212485, "evidence_share": 7.5, "evidence_share_display": "7.5", "freshness_pct": 74.3, "age_days": 2.1, "influence_label": "Medium", "duplicate_count": 3, "topics": ["Earnings", "Financials", "Healthcare", "Revenue Growth"], "evidence_basis": "", "score_included": true}, {"title": "A Profitable Rare-Disease Prize: Who Might Snap Up BioCryst?", "summary": "Quick Read BioCryst hit its first full year of profitability in 2025, with Q2 2026 revenue up 34% to $218 million, fueling acquisition speculation. Takeda (TAK) tops the buyer rankings as navenibart directly threatens its Takhzyro franchise; AstraZeneca (AZN) ranks second through its Alexion rare-disease platform. Act now: the analyst who called NVIDIA in 2010 just named his top 10 AI stocks \u2014 and BioCryst Pharmaceuticals didn't make the cut. Grab the names FREE today. BioCryst Pharmaceuticals (NASDAQ:BCRX) closed at $9.84 on August 10, 2026, giving the Durham-based rare-disease specialist a m", "url": "https://finance.yahoo.com/healthcare/articles/profitable-rare-disease-prize-might-132039632.html", "source_link": "https://finance.yahoo.com/healthcare/articles/profitable-rare-disease-prize-might-132039632.html", "source_link_is_lookup": false, "source_name": "finance.yahoo.com", "published_at": "2026-08-11T13:20:39+00:00", "published_display": "11 Aug 2026 13:20", "source_kind": "aggregator", "sentiment": "positive", "sentiment_pct": 68, "tone_signals": ["Operating growth"], "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage", "is_stale": false, "evidence_weight": 0.129259, "evidence_share": 4.5, "evidence_share_display": "4.5", "freshness_pct": 80.8, "age_days": 2.1, "influence_label": "Low", "duplicate_count": 3, "topics": ["Biotech", "Earnings", "Free Cash Flow", "Guidance", "M A", "Operating Income"], "evidence_basis": "", "score_included": true}, {"title": "AstraZeneca stock outlook: Seller pressure limits upside for AZN", "summary": "", "url": "https://news.google.com/rss/articles/CBMimAFBVV95cUxOZThtUFlzWXR2U21QZl9RT0p4OUt4bngtN2lOWWx2Yk81aU5NNGJVTzVSazZQcWF0b0ltbTVIRm40elJRWVQweC1OTHZrUEprNExZek1PcVJRUHkzTW1hdEVnVTBlelV6SDlwOGFNUFhzS0UxY1kxVnljOVhyY084MUN1eEFGVzUyb05fWUZzWlpJMW1FdHJJTA?oc=5", "source_link": "https://news.google.com/rss/articles/CBMimAFBVV95cUxOZThtUFlzWXR2U21QZl9RT0p4OUt4bngtN2lOWWx2Yk81aU5NNGJVTzVSazZQcWF0b0ltbTVIRm40elJRWVQweC1OTHZrUEprNExZek1PcVJRUHkzTW1hdEVnVTBlelV6SDlwOGFNUFhzS0UxY1kxVnljOVhyY084MUN1eEFGVzUyb05fWUZzWlpJMW1FdHJJTA?oc=5", "source_link_is_lookup": false, "source_name": "Traders Union", "published_at": "2026-08-11T08:02:34+00:00", "published_display": "11 Aug 2026 08:02", "source_kind": "publisher", "sentiment": "positive", "sentiment_pct": 57, "tone_signals": ["Positive financial language"], "event_type": "guidance", "event_label": "Guidance", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage", "is_stale": false, "evidence_weight": 0.108248, "evidence_share": 3.8, "evidence_share_display": "3.8", "freshness_pct": 79.1, "age_days": 2.4, "influence_label": "Low", "duplicate_count": 2, "topics": [], "evidence_basis": "headline_only", "score_included": true}, {"title": "Jim Cramer Recommends Goldman Sachs and Morgan Stanley to Profit From Accelerating M&A Deals", "summary": "During Mad Money's August 6 episode, host Jim Cramer highlighted why investors should target elite advisory firms rather than speculating on acquisition targets, as he said: Here's a big theme that right now really only impacts two large companies: pent-up demand for mergers and acquisitions now that the Biden era of overzealous antitrust enforcement has been replaced by the Trump era of almost non-existent antitrust enforcement. Most companies don't believe this moment can last, so they're taking advantage of it to make deals. When the summer's over, I believe we're going to come back to see ", "url": "https://finance.yahoo.com/markets/stocks/articles/jim-cramer-recommends-goldman-sachs-054332862.html", "source_link": "https://finance.yahoo.com/markets/stocks/articles/jim-cramer-recommends-goldman-sachs-054332862.html", "source_link_is_lookup": false, "source_name": "finance.yahoo.com", "published_at": "2026-08-11T05:43:32+00:00", "published_display": "11 Aug 2026 05:43", "source_kind": "aggregator", "sentiment": "positive", "sentiment_pct": 82, "tone_signals": ["Improving financial comparison"], "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 96, "tier": "direct", "tier_label": "Direct company coverage", "is_stale": false, "evidence_weight": 0.174268, "evidence_share": 6.1, "evidence_share_display": "6.1", "freshness_pct": 78.3, "age_days": 2.5, "influence_label": "Low", "duplicate_count": 3, "topics": ["Earnings", "Earnings Per Share", "Earnings Report", "Financial Results", "Financials", "Fourth Quarter"], "evidence_basis": "", "score_included": true}, {"title": "Can AstraZeneca (AZN) Reach Its $80 Billion Revenue Goal Despite Clinical Setbacks?", "summary": "It was reported on July 27 that AstraZeneca PLC (NASDAQ:AZN) shares outperformed in European trading after the company reported second-quarter earnings that beat Wall Street expectations and reiterated its full-year 2026 guidance. Core earnings per share (EPS) jumped 18% on a constant exchange rate (FXN) basis year-over-year to $2.63, comfortably ahead of the $2.48 analyst consensus. Total revenue reached $15.38 billion, up 5% at constant exchange rates, driven primarily by sustained momentum in its Oncology and Rare Disease units. Management reconfirmed its full-year 2026 outlook of mid-to-hi", "url": "https://finance.yahoo.com/healthcare/articles/astrazeneca-azn-reach-80-billion-234403667.html", "source_link": "https://finance.yahoo.com/healthcare/articles/astrazeneca-azn-reach-80-billion-234403667.html", "source_link_is_lookup": false, "source_name": "finance.yahoo.com", "published_at": "2026-08-10T23:44:03+00:00", "published_display": "10 Aug 2026 23:44", "source_kind": "aggregator", "sentiment": "positive", "sentiment_pct": 76, "tone_signals": ["Beat expectations", "Strong Demand", "Operating deterioration", "Operating growth"], "event_type": "earnings", "event_label": "Earnings", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage", "is_stale": false, "evidence_weight": 0.176388, "evidence_share": 6.2, "evidence_share_display": "6.2", "freshness_pct": 68.6, "age_days": 2.7, "influence_label": "Low", "duplicate_count": 3, "topics": ["Balance Sheet", "Clinical Trials", "Dividends", "Earnings", "Earnings Growth", "Earnings Per Share"], "evidence_basis": "", "score_included": true}, {"title": "Jim Cramer Highlights Pharmaceutical Giants as Non-Tech Innovation Plays Like JNJ and LLY", "summary": "During the August 6 episode of CNBC's Mad Money, Jim Cramer pointed to a growing sector rotation as portfolio managers look for innovation outside the mega-cap technology space. He said: Finally, tech had such a run that portfolio managers want exposure to other sectors of the market that still have innovation. Think of them as non- tech tech stocks. For the\u2026 Charitable Trust club, we've been emphasizing Eli Lilly and Johnson & Johnson. And we talked about these\u2026 I talked about them at length with Jeff Marks today at our 10:20 call. They both had terrific quarters and deserve to be bought on a", "url": "https://finance.yahoo.com/healthcare/articles/jim-cramer-highlights-pharmaceutical-giants-180730894.html", "source_link": "https://finance.yahoo.com/healthcare/articles/jim-cramer-highlights-pharmaceutical-giants-180730894.html", "source_link_is_lookup": false, "source_name": "finance.yahoo.com", "published_at": "2026-08-10T18:07:30+00:00", "published_display": "10 Aug 2026 18:07", "source_kind": "aggregator", "sentiment": "neutral", "sentiment_pct": 55, "tone_signals": ["Deteriorating financial comparison", "Operating growth"], "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage", "is_stale": false, "evidence_weight": 0.088433, "evidence_share": 3.1, "evidence_share_display": "3.1", "freshness_pct": 66.4, "age_days": 3.0, "influence_label": "Low", "duplicate_count": 3, "topics": ["Balance Sheet", "Biotech", "Fda Approval", "Fourth Quarter", "Healthcare", "M A"], "evidence_basis": "", "score_included": true}, {"title": "AstraZeneca PLC (AZN) Stock Analysis: Unveiling a 32% Potential Upside Amid Strong Buy Ratings", "summary": "", "url": "https://news.google.com/rss/articles/CBMi2AFBVV95cUxPbzRBN01Qd280NC1Zenlfdy1ySDNDeDZKU0tFZGx5eDJqS2pOeTJ1YmY0VkdNVHl2NjJsLUl6NzZZRF9Ra1hRWXBJU1lmWnFub0llLTB3ZDZnLTFSa2prTHh0aEdvMTBfUHpuUG9wcFNpaHg0Ml94bGdQMWF5QUlnM210a1lHVVJJSTA5WG15ekFaeFhQNnNiX1VKTWVsVW5uc2UzazNKeFVOQUk5S3dfV1VNODE5QUE0SDZhZ3psbnczWWprSDNMZHBjMFBfTlRHMEdSN2pNZ0w?oc=5", "source_link": "https://news.google.com/rss/articles/CBMi2AFBVV95cUxPbzRBN01Qd280NC1Zenlfdy1ySDNDeDZKU0tFZGx5eDJqS2pOeTJ1YmY0VkdNVHl2NjJsLUl6NzZZRF9Ra1hRWXBJU1lmWnFub0llLTB3ZDZnLTFSa2prTHh0aEdvMTBfUHpuUG9wcFNpaHg0Ml94bGdQMWF5QUlnM210a1lHVVJJSTA5WG15ekFaeFhQNnNiX1VKTWVsVW5uc2UzazNKeFVOQUk5S3dfV1VNODE5QUE0SDZhZ3psbnczWWprSDNMZHBjMFBfTlRHMEdSN2pNZ0w?oc=5", "source_link_is_lookup": false, "source_name": "DirectorsTalk Interviews", "published_at": "2026-08-10T09:20:03+00:00", "published_display": "10 Aug 2026 09:20", "source_kind": "publisher", "sentiment": "positive", "sentiment_pct": 63, "tone_signals": ["Positive financial language"], "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage", "is_stale": false, "evidence_weight": 0.029139, "evidence_share": 1.0, "evidence_share_display": "1", "freshness_pct": 31.7, "age_days": 3.3, "influence_label": "Low", "duplicate_count": 2, "topics": [], "evidence_basis": "headline_only", "score_included": true}, {"title": "Zimmer Biomet Q2 Earnings Call Highlights", "summary": "Key Points Interested in Zimmer Biomet Holdings, Inc.? Here are five stocks we like better. Zimmer Biomet reported solid Q2 growth: Net sales rose 4.8% to $2.177 billion, driven by hips, specialty businesses and technology. Adjusted EPS was $2.07, while U.S. organic sales increased 4.6%. Technology and hip products led performance: Hip sales grew 5.1%, while technology, data, bone cement and surgical sales surged 21.5%, supported by strong ROSA, TMINI and OrthoGrid adoption. Knee sales were nearly flat, with international weakness\u2014especially in China\u2014offsetting U.S. gains. Zimmer Biomet raised", "url": "https://finance.yahoo.com/healthcare/articles/zimmer-biomet-q2-earnings-call-180350126.html", "source_link": "https://finance.yahoo.com/healthcare/articles/zimmer-biomet-q2-earnings-call-180350126.html", "source_link_is_lookup": false, "source_name": "finance.yahoo.com", "published_at": "2026-08-09T18:03:50+00:00", "published_display": "09 Aug 2026 18:03", "source_kind": "aggregator", "sentiment": "positive", "sentiment_pct": 90, "tone_signals": ["Improving financial comparison", "Operating growth"], "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage", "is_stale": false, "evidence_weight": 0.186901, "evidence_share": 6.6, "evidence_share_display": "6.6", "freshness_pct": 57.8, "age_days": 4.0, "influence_label": "Low", "duplicate_count": 3, "topics": ["Earnings", "Earnings Per Share", "Free Cash Flow", "Growth Rate", "Guidance", "Healthcare"], "evidence_basis": "archived_article", "score_included": true}, {"title": "Notable healthcare headlines for the week: Eli Lilly, Novo Nordisk, and Pfizer in focus", "summary": "Wall Street\u2019s major market averages ended higher on Friday after July's nonfarm payrolls surprised to the downside, showing an unexpected contraction in employment. The blue-chip Dow edged up 0.3%, the benchmark S&P 500 gained 0.62%, and the tech-focused Nasdaq Composite jumped 1.3%. The S&P 500 Health Care Index Sector (XLV [https://seekingalpha.com/symbol/XLV]) gained 1.92% during the week. The top S&P 500 healthcare gainers and losers for the last week are as follows: TOP GAINERS: Charles River Laboratories International (CRL [https://seekingalpha.com/symbol/CRL]) +15.04% Veeva Systems (VEE", "url": "https://seekingalpha.com/news/4629554-notable-healthcare-headlines-for-the-week-eli-lilly-novo-nordisk-and-pfizer-in-focus?amp%3Butm_medium=referral&amp%3Bfeed_item_type=news", "source_link": "https://seekingalpha.com/news/4629554-notable-healthcare-headlines-for-the-week-eli-lilly-novo-nordisk-and-pfizer-in-focus?amp%3Butm_medium=referral&amp%3Bfeed_item_type=news", "source_link_is_lookup": false, "source_name": "seekingalpha.com", "published_at": "2026-08-09T13:05:04+00:00", "published_display": "09 Aug 2026 13:05", "source_kind": "publisher", "sentiment": "positive", "sentiment_pct": 74, "tone_signals": ["Beat expectations", "Guidance raised", "Improving financial comparison", "Operating deterioration"], "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage", "is_stale": false, "evidence_weight": 0.149429, "evidence_share": 5.3, "evidence_share_display": "5.3", "freshness_pct": 56.2, "age_days": 4.2, "influence_label": "Low", "duplicate_count": 3, "topics": ["Consensus Estimate", "Earnings", "Earnings Per Share", "Guidance", "Healthcare", "M A"], "evidence_basis": "", "score_included": true}, {"title": "SA Asks: What's the outlook for Big Pharma M&A?", "summary": "[Medical research with pipette and test tube, DNA analysis, biotechnology, genetic science and healthcare] jittawit.21 Big Pharma moved back into the spotlight last week following a Financial Times report that Bristol Myers Squibb (BMY [https://seekingalpha.com/symbol/BMY]) was in merger talks with AstraZeneca (AZN [https://seekingalpha.com/symbol/AZN]), a development that was later denied by unnamed sources to Reuters. We asked Seeking Alpha analysts Stephen Ayers [https://seekingalpha.com/author/stephen-ayers], ALLKA Research [https://seekingalpha.com/author/allka-research], and Chris DeMuth", "url": "https://seekingalpha.com/news/4629652-sa-asks-whats-the-outlook-for-big-pharma-ma?amp%3Butm_medium=referral&amp%3Bfeed_item_type=news", "source_link": "https://seekingalpha.com/news/4629652-sa-asks-whats-the-outlook-for-big-pharma-ma?amp%3Butm_medium=referral&amp%3Bfeed_item_type=news", "source_link_is_lookup": false, "source_name": "seekingalpha.com", "published_at": "2026-08-08T19:28:35+00:00", "published_display": "08 Aug 2026 19:28", "source_kind": "publisher", "sentiment": "negative", "sentiment_pct": 34, "tone_signals": ["Operating deterioration"], "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage", "is_stale": false, "evidence_weight": 0.103605, "evidence_share": 3.6, "evidence_share_display": "3.6", "freshness_pct": 61.6, "age_days": 4.9, "influence_label": "Low", "duplicate_count": 3, "topics": ["Biotech", "Fda Approval", "M A", "M&a", "Oncology", "Pharma"], "evidence_basis": "", "score_included": true}, {"title": "Trending stocks this week as SpaceX, Palantir earnings and jobs data drive markets", "summary": "[Wall Street New York stock exchange stock market] alexsl Wall Street ended the week higher, with the Dow Jones Industrial Average (DJI [https://seekingalpha.com/symbol/DJI]) and the S&P 500 (SP500 [https://seekingalpha.com/symbol/SP500]) closing at record highs as investors weighed a deluge of corporate earnings, including results from SpaceX (SPCX [https://seekingalpha.com/symbol/SPCX]) and Palantir Technologies (PLTR [https://seekingalpha.com/symbol/PLTR]), alongside weaker-than-expected U.S. payrolls data. U.S. nonfarm payrolls fell by 23,000 in July, missing economists' expectations for a", "url": "https://seekingalpha.com/news/4629310-trending-stocks-this-week-as-spacex-palantir-earnings-and-jobs-data-drive-markets?amp%3Butm_medium=referral&amp%3Bfeed_item_type=news", "source_link": "https://seekingalpha.com/news/4629310-trending-stocks-this-week-as-spacex-palantir-earnings-and-jobs-data-drive-markets?amp%3Butm_medium=referral&amp%3Bfeed_item_type=news", "source_link_is_lookup": false, "source_name": "seekingalpha.com", "published_at": "2026-08-08T17:12:36+00:00", "published_display": "08 Aug 2026 17:12", "source_kind": "publisher", "sentiment": "positive", "sentiment_pct": 78, "tone_signals": ["Beat expectations", "Missed expectations", "Guidance raised", "Improving financial comparison"], "event_type": "earnings", "event_label": "Earnings", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage", "is_stale": false, "evidence_weight": 0.145928, "evidence_share": 5.1, "evidence_share_display": "5.1", "freshness_pct": 50.1, "age_days": 5.0, "influence_label": "Low", "duplicate_count": 3, "topics": ["AI", "Consensus Estimate", "Earnings", "Earnings Per Share", "Earnings Report", "Fourth Quarter"], "evidence_basis": "", "score_included": true}, {"title": "AstraZeneca (LSE:AZN) Signs Two Cancer Diagnostics Deals To Widen Patient Access", "summary": "Make better investment decisions with Simply Wall St's easy, visual tools that give you a competitive edge. SOPHiA GENETICS and AstraZeneca (LSE:AZN) have entered a global partnership to develop and launch two decentralized companion diagnostics in precision oncology. The multi-year collaboration focuses on clinical trial assays that support development and commercialization of AstraZeneca's oncology therapies. The partners aim to expand access to personalized cancer treatments by enabling decentralized testing across a wider range of clinical settings. For readers tracking how data driven too", "url": "https://finance.yahoo.com/healthcare/articles/astrazeneca-lse-azn-signs-two-151237153.html", "source_link": "https://finance.yahoo.com/healthcare/articles/astrazeneca-lse-azn-signs-two-151237153.html", "source_link_is_lookup": false, "source_name": "finance.yahoo.com", "published_at": "2026-08-08T15:12:37+00:00", "published_display": "08 Aug 2026 15:12", "source_kind": "aggregator", "sentiment": "positive", "sentiment_pct": 72, "tone_signals": ["Operating growth"], "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage", "is_stale": false, "evidence_weight": 0.105893, "evidence_share": 3.7, "evidence_share_display": "3.7", "freshness_pct": 60.5, "age_days": 5.1, "influence_label": "Low", "duplicate_count": 3, "topics": ["Clinical Trials", "Oncology", "Partnership", "Pharma", "Precision Medicine", "Share Price"], "evidence_basis": "", "score_included": true}, {"title": "Parallel Advisors LLC Purchases New Position in Astrazeneca Plc $AZN", "summary": "", "url": "", "source_link": "https://www.google.com/search?tbm=nws&q=%22Parallel+Advisors+LLC+Purchases+New+Position+in+Astrazeneca+Plc+%24AZN%22+%22MarketBeat%22", "source_link_is_lookup": true, "source_name": "MarketBeat", "published_at": "2026-08-08T09:18:55+00:00", "published_display": "08 Aug 2026 09:18", "source_kind": "publisher", "sentiment": "neutral", "sentiment_pct": 50, "tone_signals": [], "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage", "is_stale": false, "evidence_weight": 0.008467, "evidence_share": 0.3, "evidence_share_display": "0.3", "freshness_pct": 15.8, "age_days": 5.3, "influence_label": "Low", "duplicate_count": 1, "topics": [], "evidence_basis": "headline_only", "score_included": true}, {"title": "Roche Stock Jumps as Morgan Stanley Sees Drug Breakout", "summary": "This article first appeared on GuruFocus. Roche Holding (RHHBY), the Swiss pharmaceutical and diagnostics giant, got a major Wall Street vote of confidence after Morgan Stanley upgraded the stock to Overweight from Equal Weight and hiked its ADR price target to $63 from $46. The upgrade helped send Roche's U.S.-traded ADRs up about 2.2% to $57.38 during Friday's session. Morgan Stanley also swapped out AstraZeneca as its top pharmaceutical pick in favor of Roche, a clear sign the bank believes the company's next growth story is gaining momentum. Warning! GuruFocus has detected 7 Warning Signs ", "url": "https://finance.yahoo.com/healthcare/articles/roche-stock-jumps-morgan-stanley-193033041.html", "source_link": "https://finance.yahoo.com/healthcare/articles/roche-stock-jumps-morgan-stanley-193033041.html", "source_link_is_lookup": false, "source_name": "finance.yahoo.com", "published_at": "2026-08-07T19:30:33+00:00", "published_display": "07 Aug 2026 19:30", "source_kind": "aggregator", "sentiment": "positive", "sentiment_pct": 70, "tone_signals": ["Analyst upgrade", "Positive market reaction"], "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage", "is_stale": false, "evidence_weight": 0.044031, "evidence_share": 1.5, "evidence_share_display": "1.5", "freshness_pct": 25.6, "age_days": 5.9, "influence_label": "Low", "duplicate_count": 3, "topics": ["Earnings Estimate", "Fda Approval", "Intrinsic Value", "Pharma", "Price Target"], "evidence_basis": "", "score_included": true}, {"title": "Deal or No Deal, AstraZeneca Stock Is a Bargain", "summary": "", "url": "", "source_link": "https://www.google.com/search?tbm=nws&q=%22Deal+or+No+Deal%2C+AstraZeneca+Stock+Is+a+Bargain%22+%22WSJ%22", "source_link_is_lookup": true, "source_name": "WSJ", "published_at": "2026-08-07T06:39:44.346317+00:00", "published_display": "07 Aug 2026 06:39", "source_kind": "editorial_wire", "sentiment": "neutral", "sentiment_pct": 50, "tone_signals": [], "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage", "is_stale": false, "evidence_weight": 0.065297, "evidence_share": 2.3, "evidence_share_display": "2.3", "freshness_pct": 52.9, "age_days": 6.4, "influence_label": "Low", "duplicate_count": 1, "topics": [], "evidence_basis": "headline_only", "score_included": true}, {"title": "AstraZeneca Stock Drops 7% as Merger Talks With Bristol Myers Squibb Surface", "summary": "", "url": "", "source_link": "https://www.google.com/search?tbm=nws&q=%22AstraZeneca+Stock+Drops+7%25+as+Merger+Talks+With+Bristol+Myers+Squibb+Surface%22+%22TIKR.com%22", "source_link_is_lookup": true, "source_name": "TIKR.com", "published_at": "2026-08-05T05:39:41.286232+00:00", "published_display": "05 Aug 2026 05:39", "source_kind": "publisher", "sentiment": "negative", "sentiment_pct": 40, "tone_signals": ["Negative market reaction"], "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage", "is_stale": false, "evidence_weight": 0.057072, "evidence_share": 2.0, "evidence_share_display": "2", "freshness_pct": 43.2, "age_days": 8.5, "influence_label": "Low", "duplicate_count": 1, "topics": [], "evidence_basis": "headline_only", "score_included": true}, {"title": "Share price plummets as drugs giant AstraZeneca holds talks over possible merger | ITV News", "summary": "", "url": "https://news.google.com/rss/articles/CBMiwAFBVV95cUxQanBod0VpVmdXTDgwVkpUQU5xZUxnNmRRZm85QVRQVmg3YUhka0c1RkVQVmcxeFJtR1V2Ym1iOXc1UHRGa3g0ek9YRU96YzBQdHIxYXBad2ljb21icDhnN3FCSjA3ZE0xdTdNM1M4NkF6R2dzb0dpWWxMNk1YWHkyMTJqX2NoSWtnRWEtSWlMLVlMNENOb0oxMTBrU0lsLVhKY2ZqY3lpUkxyaEw3RGdEZ1p0MDhtNkNNUU0wQWk0YVM?oc=5", "source_link": "https://news.google.com/rss/articles/CBMiwAFBVV95cUxQanBod0VpVmdXTDgwVkpUQU5xZUxnNmRRZm85QVRQVmg3YUhka0c1RkVQVmcxeFJtR1V2Ym1iOXc1UHRGa3g0ek9YRU96YzBQdHIxYXBad2ljb21icDhnN3FCSjA3ZE0xdTdNM1M4NkF6R2dzb0dpWWxMNk1YWHkyMTJqX2NoSWtnRWEtSWlMLVlMNENOb0oxMTBrU0lsLVhKY2ZqY3lpUkxyaEw3RGdEZ1p0MDhtNkNNUU0wQWk0YVM?oc=5", "source_link_is_lookup": false, "source_name": "ITVX", "published_at": "2026-08-03T07:00:00+00:00", "published_display": "03 Aug 2026 07:00", "source_kind": "publisher", "sentiment": "neutral", "sentiment_pct": 50, "tone_signals": [], "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage", "is_stale": false, "evidence_weight": 0.026402, "evidence_share": 0.9, "evidence_share_display": "0.9", "freshness_pct": 35.7, "age_days": 10.4, "influence_label": "Low", "duplicate_count": 2, "topics": [], "evidence_basis": "headline_only", "score_included": true}, {"title": "AstraZeneca (NYSE:AZN)\u2013Bristol Myers Squibb (NYSE:BMY): Potential $455 Billion Tie-Up Raises Questions Over Deal Value", "summary": "", "url": "", "source_link": "https://www.google.com/search?tbm=nws&q=%22AstraZeneca+%28NYSE%3AAZN%29%E2%80%93Bristol+Myers+Squibb+%28NYSE%3ABMY%29%3A+Potential+%24455+Billion+Tie-Up+Raises+Questions+Over+Deal+Value%22+%22TechStock%C2%B2%22", "source_link_is_lookup": true, "source_name": "TechStock\u00b2", "published_at": "2026-08-03T00:29:47.619070+00:00", "published_display": "03 Aug 2026 00:29", "source_kind": "publisher", "sentiment": "positive", "sentiment_pct": 57, "tone_signals": ["Positive financial language"], "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage", "is_stale": false, "evidence_weight": 0.035639, "evidence_share": 1.3, "evidence_share_display": "1.3", "freshness_pct": 34.7, "age_days": 10.7, "influence_label": "Low", "duplicate_count": 1, "topics": [], "evidence_basis": "headline_only", "score_included": true}, {"title": "AstraZeneca (LSE:AZN) Stock Looks Cheap On Cash Flow While Broader Checks Stay Mixed", "summary": "", "url": "", "source_link": "https://www.google.com/search?tbm=nws&q=%22AstraZeneca+%28LSE%3AAZN%29+Stock+Looks+Cheap+On+Cash+Flow+While+Broader+Checks+Stay+Mixed%22+%22webull.com%22", "source_link_is_lookup": true, "source_name": "webull.com", "published_at": "2026-08-02T18:26:44.950107+00:00", "published_display": "02 Aug 2026 18:26", "source_kind": "publisher", "sentiment": "neutral", "sentiment_pct": 50, "tone_signals": [], "event_type": "liquidity", "event_label": "Balance sheet", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage", "is_stale": false, "evidence_weight": 0.032033, "evidence_share": 1.1, "evidence_share_display": "1.1", "freshness_pct": 33.9, "age_days": 10.9, "influence_label": "Low", "duplicate_count": 1, "topics": [], "evidence_basis": "headline_only", "score_included": true}, {"title": "Astrazeneca (AZN) Short Interest & Short Float | Updated Aug 2026 $AZN", "summary": "", "url": "", "source_link": "https://www.google.com/search?tbm=nws&q=%22Astrazeneca+%28AZN%29+Short+Interest+%26+Short+Float+%7C+Updated+Aug+2026+%24AZN%22+%22MarketBeat%22", "source_link_is_lookup": true, "source_name": "MarketBeat", "published_at": "2026-08-02T12:03:08.777546+00:00", "published_display": "02 Aug 2026 12:03", "source_kind": "publisher", "sentiment": "neutral", "sentiment_pct": 50, "tone_signals": [], "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage", "is_stale": false, "evidence_weight": 0.001101, "evidence_share": 0.0, "evidence_share_display": "<0.1", "freshness_pct": 2.1, "age_days": 11.2, "influence_label": "Low", "duplicate_count": 1, "topics": [], "evidence_basis": "headline_only", "score_included": true}, {"title": "Xencor rises as AstraZeneca royalty row ends (XNCR:NASDAQ)", "summary": "", "url": "", "source_link": "https://www.google.com/search?tbm=nws&q=%22Xencor+rises+as+AstraZeneca+royalty+row+ends+%28XNCR%3ANASDAQ%29%22+%22Seeking+Alpha%22", "source_link_is_lookup": true, "source_name": "Seeking Alpha", "published_at": "2026-07-31T13:52:55.826612+00:00", "published_display": "31 Jul 2026 13:52", "source_kind": "publisher", "sentiment": "neutral", "sentiment_pct": 50, "tone_signals": [], "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage", "is_stale": false, "evidence_weight": 0.00066, "evidence_share": 0.0, "evidence_share_display": "<0.1", "freshness_pct": 1.1, "age_days": 13.1, "influence_label": "Low", "duplicate_count": 1, "topics": [], "evidence_basis": "headline_only", "score_included": true}, {"title": "Fund Update: 42,335 ASTRAZENECA (AZN) shares added to STEPHENS INC |AR| portfolio", "summary": "", "url": "", "source_link": "https://www.google.com/search?tbm=nws&q=%22Fund+Update%3A+42%2C335+ASTRAZENECA+%28AZN%29+shares+added+to+STEPHENS+INC+%7CAR%7C+portfolio%22+%22Quiver+Quantitative%22", "source_link_is_lookup": true, "source_name": "Quiver Quantitative", "published_at": "2026-07-30T06:49:43.156285+00:00", "published_display": "30 Jul 2026 06:49", "source_kind": "publisher", "sentiment": "neutral", "sentiment_pct": 50, "tone_signals": [], "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage", "is_stale": false, "evidence_weight": 0.000361, "evidence_share": 0.0, "evidence_share_display": "<0.1", "freshness_pct": 0.7, "age_days": 14.4, "influence_label": "Low", "duplicate_count": 1, "topics": [], "evidence_basis": "headline_only", "score_included": true}, {"title": "AstraZeneca (AZN) Cash Flow Statement", "summary": "", "url": "", "source_link": "https://www.google.com/search?tbm=nws&q=%22AstraZeneca+%28AZN%29+Cash+Flow+Statement%22+%22Moomoo%22", "source_link_is_lookup": true, "source_name": "Moomoo", "published_at": "2026-07-29T06:59:42.412453+00:00", "published_display": "29 Jul 2026 06:59", "source_kind": "publisher", "sentiment": "neutral", "sentiment_pct": 50, "tone_signals": [], "event_type": "liquidity", "event_label": "Balance sheet", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage", "is_stale": false, "evidence_weight": 0.020562, "evidence_share": 0.7, "evidence_share_display": "0.7", "freshness_pct": 21.7, "age_days": 15.4, "influence_label": "Low", "duplicate_count": 1, "topics": [], "evidence_basis": "headline_only", "score_included": true}, {"title": "AstraZeneca (AZN) Earnings Report Anticipated as Wall Street Clo", "summary": "", "url": "", "source_link": "https://www.google.com/search?tbm=nws&q=%22AstraZeneca+%28AZN%29+Earnings+Report+Anticipated+as+Wall+Street+Clo%22+%22GuruFocus%22", "source_link_is_lookup": true, "source_name": "GuruFocus", "published_at": "2026-07-27T00:29:41.681250+00:00", "published_display": "27 Jul 2026 00:29", "source_kind": "publisher", "sentiment": "neutral", "sentiment_pct": 50, "tone_signals": [], "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage", "is_stale": false, "evidence_weight": 0.007087, "evidence_share": 0.2, "evidence_share_display": "0.2", "freshness_pct": 8.6, "age_days": 17.7, "influence_label": "Low", "duplicate_count": 1, "topics": [], "evidence_basis": "headline_only", "score_included": true}, {"title": "AstraZeneca PLC (LSE:AZN) Q2 2026: Everything You Need To Know A", "summary": "", "url": "", "source_link": "https://www.google.com/search?tbm=nws&q=%22AstraZeneca+PLC+%28LSE%3AAZN%29+Q2+2026%3A+Everything+You+Need+To+Know+A%22+%22GuruFocus%22", "source_link_is_lookup": true, "source_name": "GuruFocus", "published_at": "2026-07-24T18:40:05.727461+00:00", "published_display": "24 Jul 2026 18:40", "source_kind": "publisher", "sentiment": "neutral", "sentiment_pct": 50, "tone_signals": [], "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage", "is_stale": false, "evidence_weight": 5.4e-05, "evidence_share": 0.0, "evidence_share_display": "<0.1", "freshness_pct": 0.1, "age_days": 19.9, "influence_label": "Low", "duplicate_count": 1, "topics": [], "evidence_basis": "headline_only", "score_included": true}, {"title": "AstraZeneca stock forecast: Consolidation near GBX12,547 support", "summary": "", "url": "https://news.google.com/rss/articles/CBMilAFBVV95cUxOaDdDcWgzdFpEalpmOUhvSnc4NGJtN1JZdUFYTzJXb1ZKa2JyaVVQaEI5QVZVTXRka1kzQW9hbWt0M2t5Tm5USFZSM0dRdzE2QVI0cnRQNU8xNmNRR2QxT041ZVEzaXI4amV3d3dEcXNWZXFqbl9YLWNGMzk1WGctY1huWG1pQTJnZ1pWN3hnZEQxQ3Rw?oc=5", "source_link": "https://news.google.com/rss/articles/CBMilAFBVV95cUxOaDdDcWgzdFpEalpmOUhvSnc4NGJtN1JZdUFYTzJXb1ZKa2JyaVVQaEI5QVZVTXRka1kzQW9hbWt0M2t5Tm5USFZSM0dRdzE2QVI0cnRQNU8xNmNRR2QxT041ZVEzaXI4amV3d3dEcXNWZXFqbl9YLWNGMzk1WGctY1huWG1pQTJnZ1pWN3hnZEQxQ3Rw?oc=5", "source_link_is_lookup": false, "source_name": "Traders Union", "published_at": "2026-07-24T07:00:00+00:00", "published_display": "24 Jul 2026 07:00", "source_kind": "publisher", "sentiment": "neutral", "sentiment_pct": 50, "tone_signals": [], "event_type": "guidance", "event_label": "Guidance", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage", "is_stale": false, "evidence_weight": 0.013078, "evidence_share": 0.5, "evidence_share_display": "0.5", "freshness_pct": 13.2, "age_days": 20.4, "influence_label": "Low", "duplicate_count": 2, "topics": [], "evidence_basis": "headline_only", "score_included": true}, {"title": "AstraZeneca's (AZN) Etcamah Secures EU Approval for Breast Cance", "summary": "", "url": "", "source_link": "https://www.google.com/search?tbm=nws&q=%22AstraZeneca%27s+%28AZN%29+Etcamah+Secures+EU+Approval+for+Breast+Cance%22+%22GuruFocus%22", "source_link_is_lookup": true, "source_name": "GuruFocus", "published_at": "2026-07-23T12:13:38.006953+00:00", "published_display": "23 Jul 2026 12:13", "source_kind": "publisher", "sentiment": "positive", "sentiment_pct": 67, "tone_signals": ["Contract or approval won"], "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage", "is_stale": false, "evidence_weight": 0.024837, "evidence_share": 0.9, "evidence_share_display": "0.9", "freshness_pct": 12.3, "age_days": 21.2, "influence_label": "Low", "duplicate_count": 1, "topics": [], "evidence_basis": "headline_only", "score_included": true}, {"title": "AstraZeneca Stock And 2 Value Picks Trading Below Cash Flow Estimates", "summary": "", "url": "", "source_link": "https://www.google.com/search?tbm=nws&q=%22AstraZeneca+Stock+And+2+Value+Picks+Trading+Below+Cash+Flow+Estimates%22+%22simplywall.st%22", "source_link_is_lookup": true, "source_name": "simplywall.st", "published_at": "2026-07-23T09:01:35.702622+00:00", "published_display": "23 Jul 2026 09:01", "source_kind": "publisher", "sentiment": "negative", "sentiment_pct": 25, "tone_signals": ["Missed expectations"], "event_type": "liquidity", "event_label": "Balance sheet", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage", "is_stale": false, "evidence_weight": 0.029739, "evidence_share": 1.0, "evidence_share_display": "1", "freshness_pct": 12.1, "age_days": 21.3, "influence_label": "Low", "duplicate_count": 1, "topics": [], "evidence_basis": "headline_only", "score_included": true}, {"title": "Astrazeneca (AZN) Falls More Steeply Than Broader Market: What Investors Need to Know", "summary": "", "url": "", "source_link": "https://www.google.com/search?tbm=nws&q=%22Astrazeneca+%28AZN%29+Falls+More+Steeply+Than+Broader+Market%3A+What+Investors+Need+to+Know%22", "source_link_is_lookup": true, "source_name": "Market source", "published_at": "2026-07-21T06:56:14.412373+00:00", "published_display": "21 Jul 2026 06:56", "source_kind": "aggregator", "sentiment": "negative", "sentiment_pct": 43, "tone_signals": ["Negative financial language"], "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage", "is_stale": false, "evidence_weight": 2e-05, "evidence_share": 0.0, "evidence_share_display": "<0.1", "freshness_pct": 0.0, "age_days": 23.4, "influence_label": "Low", "duplicate_count": 1, "topics": [], "evidence_basis": "headline_only", "score_included": true}, {"title": "AstraZeneca needs a shot in the arm to hit $80bn revenue target", "summary": "", "url": "", "source_link": "https://www.google.com/search?tbm=nws&q=%22AstraZeneca+needs+a+shot+in+the+arm+to+hit+%2480bn+revenue+target%22+%22The+Times%22", "source_link_is_lookup": true, "source_name": "The Times", "published_at": "2026-07-20T23:20:50.419575+00:00", "published_display": "20 Jul 2026 23:20", "source_kind": "publisher", "sentiment": "neutral", "sentiment_pct": 50, "tone_signals": [], "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage", "is_stale": false, "evidence_weight": 0.003065, "evidence_share": 0.1, "evidence_share_display": "0.1", "freshness_pct": 3.7, "age_days": 23.7, "influence_label": "Low", "duplicate_count": 1, "topics": [], "evidence_basis": "headline_only", "score_included": true}, {"title": "AstraZeneca (AZN) Securities Investigation Notice - Levi & Korsinsky", "summary": "", "url": "", "source_link": "https://www.google.com/search?tbm=nws&q=%22AstraZeneca+%28AZN%29+Securities+Investigation+Notice+-+Levi+%26+Korsinsky%22+%22PR+Newswire%22", "source_link_is_lookup": true, "source_name": "PR Newswire", "published_at": "2026-07-20T16:31:14.351925+00:00", "published_display": "20 Jul 2026 16:31", "source_kind": "press_release", "sentiment": "negative", "sentiment_pct": 35, "tone_signals": ["Legal or regulatory risk"], "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage", "is_stale": false, "evidence_weight": 0.019867, "evidence_share": 0.7, "evidence_share_display": "0.7", "freshness_pct": 9.3, "age_days": 24.0, "influence_label": "Low", "duplicate_count": 1, "topics": [], "evidence_basis": "headline_only", "score_included": true}, {"title": "AstraZeneca\u2019s Oncology Engine Keeps Running Despite Wainua Setback (NYSE:AZN)", "summary": "", "url": "", "source_link": "https://www.google.com/search?tbm=nws&q=%22AstraZeneca%E2%80%99s+Oncology+Engine+Keeps+Running+Despite+Wainua+Setback+%28NYSE%3AAZN%29%22+%22Seeking+Alpha%22", "source_link_is_lookup": true, "source_name": "Seeking Alpha", "published_at": "2026-07-16T09:29:43.924454+00:00", "published_display": "16 Jul 2026 09:29", "source_kind": "publisher", "sentiment": "neutral", "sentiment_pct": 50, "tone_signals": [], "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage", "is_stale": false, "evidence_weight": 3e-06, "evidence_share": 0.0, "evidence_share_display": "<0.1", "freshness_pct": 0.0, "age_days": 28.3, "influence_label": "Low", "duplicate_count": 1, "topics": [], "evidence_basis": "headline_only", "score_included": true}], "by_tier": {"direct": [{"title": "The Advertising Research Foundation Announces 2026 ARF David Ogilvy Awards Finalists", "summary": "NEW YORK, Aug. 13, 2026 /PRNewswire/ -- The Advertising Research Foundation (ARF) today announced the finalists for the 2026 ARF David Ogilvy Awards, honoring excellence in research-driven advertising and marketing. For more than 30 years, the ARF David Ogilvy Awards have recognized campaigns that demonstrate how consumer insights and research can inspire creative work that delivers measurable business results. This year's finalists represent leading brands across categories including Automotive, B2B, Cultural Fluency, Financial Services & Insurance, Food & Beverage, Health & Personal Care, Be", "url": "https://finance.yahoo.com/media-advertising/articles/advertising-research-foundation-announces-2026-150200996.html", "source_link": "https://finance.yahoo.com/media-advertising/articles/advertising-research-foundation-announces-2026-150200996.html", "source_link_is_lookup": false, "source_name": "finance.yahoo.com", "published_at": "2026-08-13T15:02:00+00:00", "published_display": "13 Aug 2026 15:02", "provider": "eodhd", "providers": ["eodhd"], "source_names": ["finance.yahoo.com"], "source_kind": "aggregator", "story_key": "21cdd6efb4f006a77a1ccec8b3e58b1a3934172bb51c9e54a5a601ca9f190457", "target_scope": "", "durable_archive": false, "archive_provider": "", "sentiment_origin": "provider_blend", "model_confidence": 0.457, "provider_directional_mass": 0.219, "relevance_score": 0.299997, "entity_mapped": true, "sentiment_conflict": 0.0, "sentiment": "positive", "sentiment_pct": 59, "tone_signals": [], "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage", "is_stale": false, "evidence_weight": 0.068825, "evidence_share": 2.4, "evidence_share_display": "2.4", "freshness_pct": 98.9, "age_days": 0.1, "influence_label": "Low", "duplicate_count": 1, "topics": [], "evidence_basis": "", "score_included": true}, {"title": "Can Keytruda Sustain Merck's Growth in the Second Half of 2026?", "summary": "Merck's MRK strong foothold in the oncology space is backed by its biggest revenue driver, Keytruda. The blockbuster PD-L1 inhibitor alone accounts for more than 55% of the company's total pharmaceutical sales. In the United States, Keytruda is approved for 44 indications spanning 19 tumor types, along with two tumor-agnostic approvals as well as for many of these indications worldwide. Notably, more than 2,800 clinical studies are currently evaluating Keytruda across multiple cancer types and treatment settings. Keytruda, approved for several types of cancers, has played an instrumental role ", "url": "https://finance.yahoo.com/healthcare/articles/keytruda-sustain-mercks-growth-second-140000696.html", "source_link": "https://finance.yahoo.com/healthcare/articles/keytruda-sustain-mercks-growth-second-140000696.html", "source_link_is_lookup": false, "source_name": "finance.yahoo.com", "published_at": "2026-08-13T14:00:00+00:00", "published_display": "13 Aug 2026 14:00", "provider": "eodhd", "providers": ["eodhd"], "source_names": ["finance.yahoo.com"], "source_kind": "aggregator", "story_key": "101ca26192ab6e98d81cd342a73465bb4ea3b94c3cf4262e0826f541a1f35522", "target_scope": "", "durable_archive": false, "archive_provider": "", "sentiment_origin": "provider_blend", "model_confidence": 0.691, "provider_directional_mass": 0.1838, "relevance_score": 0.367425, "entity_mapped": true, "sentiment_conflict": 0.844, "sentiment": "neutral", "sentiment_pct": 51, "tone_signals": ["Deteriorating financial comparison", "Operating deterioration", "Operating growth", "Positive market reaction"], "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage", "is_stale": false, "evidence_weight": 0.090644, "evidence_share": 3.2, "evidence_share_display": "3.2", "freshness_pct": 98.3, "age_days": 0.1, "influence_label": "Low", "duplicate_count": 1, "topics": ["Biosimilars", "Competition", "Earnings Per Share", "Immuno Oncology", "Oncology", "Patent Expiry"], "evidence_basis": "", "score_included": true}, {"title": "U.K. regulator reaffirms safety of childhood vaccination", "summary": "[Syringe drawing liquid medication from medical vial] zhikun sun/iStock via Getty Images Days after President Donald Trump ordered major changes to the U.S. childhood immunization schedule, the U.K. drug regulator on Wednesday reaffirmed the safety of pediatric vaccination, noting it remains one of the safest and most effective ways to fight many severe infectious diseases. Issuing an executive order to reduce the number of childhood vaccines administered in the U.S. and split the measles, mumps, and rubella vaccination into three separate shots on Monday, Trump suggested a link between vaccin", "url": "https://seekingalpha.com/news/4631498-uk-regulator-reaffirms-safety-of-childhood-vaccination?amp%3Butm_medium=referral&amp%3Bfeed_item_type=news", "source_link": "https://seekingalpha.com/news/4631498-uk-regulator-reaffirms-safety-of-childhood-vaccination?amp%3Butm_medium=referral&amp%3Bfeed_item_type=news", "source_link_is_lookup": false, "source_name": "seekingalpha.com", "published_at": "2026-08-12T13:13:40+00:00", "published_display": "12 Aug 2026 13:13", "provider": "eodhd", "providers": ["eodhd"], "source_names": ["seekingalpha.com"], "source_kind": "publisher", "story_key": "46b3f23a3cbbf72aa4fa4eff600d629dac6ffd5d600b532526e1abeb25fd4333", "target_scope": "", "durable_archive": false, "archive_provider": "", "sentiment_origin": "provider_blend", "model_confidence": 0.496, "provider_directional_mass": 0.1449, "relevance_score": 0.78, "entity_mapped": true, "sentiment_conflict": 0.0, "sentiment": "neutral", "sentiment_pct": 48, "tone_signals": ["Negative financial language"], "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage", "is_stale": false, "evidence_weight": 0.047106, "evidence_share": 1.7, "evidence_share_display": "1.7", "freshness_pct": 67.0, "age_days": 1.2, "influence_label": "Low", "duplicate_count": 3, "topics": ["Healthcare", "Regulation", "Split", "Vaccines"], "evidence_basis": "", "score_included": true}, {"title": "How AstraZeneca\u2019s $400bn deal unravelled", "summary": "One Broadway deal to start: Hollywood mogul Ari Emanuel has struck a roughly \u00a34.5bn deal to buy the theatre group behind West End venues including the Lyceum and the Savoy in a major bet that strong demand for live events is here to stay. In today's newsletter: AstraZeneca's Silver Upgrade to read this Financial Times article and get so much more. A Silver or Gold subscription plan is required to access premium news articles. Upgrade now", "url": "https://finance.yahoo.com/healthcare/articles/astrazeneca-400bn-deal-unravelled-040028643.html", "source_link": "https://finance.yahoo.com/healthcare/articles/astrazeneca-400bn-deal-unravelled-040028643.html", "source_link_is_lookup": false, "source_name": "finance.yahoo.com", "published_at": "2026-08-12T04:00:28+00:00", "published_display": "12 Aug 2026 04:00", "provider": "eodhd", "providers": ["eodhd"], "source_names": ["finance.yahoo.com"], "source_kind": "aggregator", "story_key": "dca284bb066b60bbf91f93101142188fab3d49b0b2476f9732ab4e090f4f98c0", "target_scope": "", "durable_archive": false, "archive_provider": "", "sentiment_origin": "stored_reclassified", "model_confidence": 0.621, "provider_directional_mass": null, "relevance_score": 0.78, "entity_mapped": true, "sentiment_conflict": 0.0, "sentiment": "positive", "sentiment_pct": 76, "tone_signals": ["Operating growth"], "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage", "is_stale": false, "evidence_weight": 0.116265, "evidence_share": 4.1, "evidence_share_display": "4.1", "freshness_pct": 70.1, "age_days": 1.5, "influence_label": "Low", "duplicate_count": 3, "topics": [], "evidence_basis": "archived_article", "score_included": true}, {"title": "AstraZeneca PLC (AZN) vs. Bristol-Myers Squibb Company (BMY): Wall Street Doesn\u2019t Buy This Merger Talk", "summary": "AstraZeneca PLC (NYSE:AZN) shares closed down as much as 9% on Monday, the stock's biggest one-day drop since 2020, after reports that it held merger talks with U.S. rival Bristol-Myers Squibb Company (NYSE:BMY). A combined company would be worth close to $400 billion, the fourth-largest drugmaker in the world by market value. Neither firm confirmed the talks, and people familiar with the matter told Reuters a deal may never materialize. Why Investors Can't Figure Out the Logic Bristol Myers shares actually rose as much as 6% on the news before dropping back down a bit, a very different reacti", "url": "https://finance.yahoo.com/markets/stocks/articles/astrazeneca-plc-azn-vs-bristol-193445815.html", "source_link": "https://finance.yahoo.com/markets/stocks/articles/astrazeneca-plc-azn-vs-bristol-193445815.html", "source_link_is_lookup": false, "source_name": "finance.yahoo.com", "published_at": "2026-08-11T19:34:45+00:00", "published_display": "11 Aug 2026 19:34", "provider": "eodhd", "providers": ["eodhd"], "source_names": ["finance.yahoo.com"], "source_kind": "aggregator", "story_key": "d5f6b937de223e09167f8ed5a604f4407deb20166ac658448dc0e69114a6b5ef", "target_scope": "", "durable_archive": false, "archive_provider": "", "sentiment_origin": "provider_blend", "model_confidence": 0.701, "provider_directional_mass": 0.117, "relevance_score": 0.78, "entity_mapped": true, "sentiment_conflict": 0.733, "sentiment": "neutral", "sentiment_pct": 48, "tone_signals": ["Improving financial comparison", "Dilution risk", "Negative market reaction"], "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 85, "tier": "direct", "tier_label": "Direct company coverage", "is_stale": false, "evidence_weight": 0.104564, "evidence_share": 3.7, "evidence_share_display": "3.7", "freshness_pct": 82.9, "age_days": 1.9, "influence_label": "Low", "duplicate_count": 3, "topics": ["M A", "Oncology", "Patent Expiry", "Pharma", "Split"], "evidence_basis": "", "score_included": true}, {"title": "Do Options Traders Know Something About AstraZeneca Stock We Don't?", "summary": "Investors in AstraZeneca PLC AZN need to pay close attention to the stock based on moves in the options market lately. That is because the Jan. 15, 2027 $115.00 Call had some of the highest implied volatility of all equity options today. What is Implied Volatility? Implied volatility shows how much movement the market is expecting in the future. Options with high levels of implied volatility suggest that investors in the underlying stocks are expecting a big move in one direction or the other. It could also mean there is an event coming up soon that may cause a big rally or a huge sell-off. Ho", "url": "https://finance.yahoo.com/markets/options/articles/options-traders-know-something-astrazeneca-141100595.html", "source_link": "https://finance.yahoo.com/markets/options/articles/options-traders-know-something-astrazeneca-141100595.html", "source_link_is_lookup": false, "source_name": "finance.yahoo.com", "published_at": "2026-08-11T14:11:00+00:00", "published_display": "11 Aug 2026 14:11", "provider": "eodhd", "providers": ["eodhd"], "source_names": ["finance.yahoo.com"], "source_kind": "aggregator", "story_key": "b51a9c0acb44843e99204d8fb453958beffc103c488dbbba819b3ed9a4d2d207", "target_scope": "", "durable_archive": false, "archive_provider": "", "sentiment_origin": "provider_blend", "model_confidence": 0.576, "provider_directional_mass": 0.1, "relevance_score": 0.78, "entity_mapped": true, "sentiment_conflict": 0.0, "sentiment": "positive", "sentiment_pct": 69, "tone_signals": ["Improving financial comparison"], "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage", "is_stale": false, "evidence_weight": 0.053247, "evidence_share": 1.9, "evidence_share_display": "1.9", "freshness_pct": 48.0, "age_days": 2.1, "influence_label": "Low", "duplicate_count": 3, "topics": ["Biotech", "Implied Volatility", "Options Trading"], "evidence_basis": "", "score_included": true}, {"title": "Hedge Funds are Bullish on AstraZeneca PLC (AZN)", "summary": "AstraZeneca PLC (NYSE:AZN) topped second-quarter profit expectations, with core earnings per share of $2.63 versus the $2.48 analysts expected. The firm reiterated its target of $80 billion in annual revenue by 2030. However, the quarter also brought fresh pipeline trouble: its rare disease drug Ultomiris missed its main goal in a late-stage trial for a rare blood vessel complication in adults, the latest in a string of setbacks that also includes an earlier heart drug trial failure and a breast cancer drug application that U.S. regulators rejected. Why One Trial Miss Shook Confidence in the W", "url": "https://finance.yahoo.com/healthcare/articles/hedge-funds-bullish-astrazeneca-plc-140427321.html", "source_link": "https://finance.yahoo.com/healthcare/articles/hedge-funds-bullish-astrazeneca-plc-140427321.html", "source_link_is_lookup": false, "source_name": "finance.yahoo.com", "published_at": "2026-08-11T14:04:27+00:00", "published_display": "11 Aug 2026 14:04", "provider": "eodhd", "providers": ["eodhd"], "source_names": ["finance.yahoo.com"], "source_kind": "aggregator", "story_key": "157f29885eab9b04cf8a5a81af1300536ff187ac011a500c0ee253bb620d6e35", "target_scope": "", "durable_archive": false, "archive_provider": "", "sentiment_origin": "provider_blend", "model_confidence": 0.746, "provider_directional_mass": 0.2062, "relevance_score": 0.78, "entity_mapped": true, "sentiment_conflict": 0.516, "sentiment": "positive", "sentiment_pct": 67, "tone_signals": ["Beat expectations", "Deteriorating financial comparison", "Contract or approval won", "Operating growth"], "event_type": "earnings", "event_label": "Earnings", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage", "is_stale": false, "evidence_weight": 0.15831, "evidence_share": 5.6, "evidence_share_display": "5.6", "freshness_pct": 74.5, "age_days": 2.1, "influence_label": "Low", "duplicate_count": 3, "topics": ["Earnings", "Earnings Per Share", "Oncology", "Pharma", "Regulation", "Trials"], "evidence_basis": "", "score_included": true}, {"title": "MRK Stock Up 5.6% in a Month as Estimates Fall: Buy, Hold or Sell?", "summary": "Merck's MRK stock is up 5.6% in a month. The key reason for the increase was the strong second-quarter 2026 performance. Merck beat estimates for both earnings and sales in the second quarter. Revenues in the second quarter increased 5% to $16.61 billion as higher sales of oncology drugs, including Keytruda, and contributions from new products like Winrevair, Welireg, and Capvaxive, and the Animal Health segment were partially offset by lower sales of Gardasil and some other vaccines. Sales of blockbuster PD-L1 inhibitor Keytruda increased 4% to $8.4 billion. Merck also raised its 2026 revenue", "url": "https://finance.yahoo.com/markets/stocks/articles/mrk-stock-5-6-month-134800162.html", "source_link": "https://finance.yahoo.com/markets/stocks/articles/mrk-stock-5-6-month-134800162.html", "source_link_is_lookup": false, "source_name": "finance.yahoo.com", "published_at": "2026-08-11T13:48:00+00:00", "published_display": "11 Aug 2026 13:48", "provider": "eodhd", "providers": ["eodhd"], "source_names": ["finance.yahoo.com"], "source_kind": "aggregator", "story_key": "8dc753318c40bcc1666bbc6fb48d58022a30d0148989be9442b7bb88150302e2", "target_scope": "", "durable_archive": false, "archive_provider": "", "sentiment_origin": "provider_blend", "model_confidence": 0.787, "provider_directional_mass": 0.227, "relevance_score": 0.78, "entity_mapped": true, "sentiment_conflict": 0.23, "sentiment": "positive", "sentiment_pct": 79, "tone_signals": ["Beat expectations", "Guidance raised", "Improving financial comparison", "Operating growth"], "event_type": "earnings", "event_label": "Earnings", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage", "is_stale": false, "evidence_weight": 0.206501, "evidence_share": 7.3, "evidence_share_display": "7.3", "freshness_pct": 74.4, "age_days": 2.1, "influence_label": "Low", "duplicate_count": 3, "topics": ["Acquisitions", "Earnings", "Oncology", "Patent Expiration", "Pharmaceuticals", "Revenue Growth"], "evidence_basis": "", "score_included": true}, {"title": "Polen International Equity adds NOK, MUFG; exits AIVAF, RNMBF among Q2 moves", "summary": "Polen International Equity Strategy outperformed the MSCI ACWI ex-US Index in the second quarter of 2026, returning 21.59% gross and 21.35% net of fees, respectively, versus 14.49% for the benchmark. During the quarter, the fund initiated new positions in ASPEED Technology, Ryohin Keikaku (RYKKF [https://seekingalpha.com/symbol/RYKKF]), Mitsubishi UFJ Financial Group (MUFG [https://seekingalpha.com/symbol/MUFG]), Tokio Marine Holdings (TKOMF [https://seekingalpha.com/symbol/TKOMF]), AstraZeneca (AZN [https://seekingalpha.com/symbol/AZN]), Nokia (NOK [https://seekingalpha.com/symbol/NOK]), Rent", "url": "https://seekingalpha.com/news/4630721-polen-international-equity-adds-nok-mufg-exits-aivaf-rnmbf-among-q2-moves?amp%3Butm_medium=referral&amp%3Bfeed_item_type=news", "source_link": "https://seekingalpha.com/news/4630721-polen-international-equity-adds-nok-mufg-exits-aivaf-rnmbf-among-q2-moves?amp%3Butm_medium=referral&amp%3Bfeed_item_type=news", "source_link_is_lookup": false, "source_name": "seekingalpha.com", "published_at": "2026-08-11T13:36:48+00:00", "published_display": "11 Aug 2026 13:36", "provider": "eodhd", "providers": ["eodhd"], "source_names": ["seekingalpha.com"], "source_kind": "publisher", "story_key": "5163a6f26c9a175deb8acba38edfd2997987adb8c3d49093fb12a769f084512d", "target_scope": "", "durable_archive": false, "archive_provider": "", "sentiment_origin": "provider_blend", "model_confidence": 0.709, "provider_directional_mass": 0.102, "relevance_score": 0.78, "entity_mapped": true, "sentiment_conflict": 0.0, "sentiment": "positive", "sentiment_pct": 82, "tone_signals": ["Beat expectations", "Operating growth"], "event_type": "earnings", "event_label": "Earnings", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage", "is_stale": false, "evidence_weight": 0.212485, "evidence_share": 7.5, "evidence_share_display": "7.5", "freshness_pct": 74.3, "age_days": 2.1, "influence_label": "Medium", "duplicate_count": 3, "topics": ["Earnings", "Financials", "Healthcare", "Revenue Growth"], "evidence_basis": "", "score_included": true}, {"title": "A Profitable Rare-Disease Prize: Who Might Snap Up BioCryst?", "summary": "Quick Read BioCryst hit its first full year of profitability in 2025, with Q2 2026 revenue up 34% to $218 million, fueling acquisition speculation. Takeda (TAK) tops the buyer rankings as navenibart directly threatens its Takhzyro franchise; AstraZeneca (AZN) ranks second through its Alexion rare-disease platform. Act now: the analyst who called NVIDIA in 2010 just named his top 10 AI stocks \u2014 and BioCryst Pharmaceuticals didn't make the cut. Grab the names FREE today. BioCryst Pharmaceuticals (NASDAQ:BCRX) closed at $9.84 on August 10, 2026, giving the Durham-based rare-disease specialist a m", "url": "https://finance.yahoo.com/healthcare/articles/profitable-rare-disease-prize-might-132039632.html", "source_link": "https://finance.yahoo.com/healthcare/articles/profitable-rare-disease-prize-might-132039632.html", "source_link_is_lookup": false, "source_name": "finance.yahoo.com", "published_at": "2026-08-11T13:20:39+00:00", "published_display": "11 Aug 2026 13:20", "provider": "eodhd", "providers": ["eodhd"], "source_names": ["finance.yahoo.com"], "source_kind": "aggregator", "story_key": "03fdb7a288edfc21b40514616b180e7d9df53c218807c001e9d74b6a285253d5", "target_scope": "", "durable_archive": false, "archive_provider": "", "sentiment_origin": "provider_blend", "model_confidence": 0.612, "provider_directional_mass": 0.155, "relevance_score": 0.78, "entity_mapped": true, "sentiment_conflict": 0.256, "sentiment": "positive", "sentiment_pct": 68, "tone_signals": ["Operating growth"], "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage", "is_stale": false, "evidence_weight": 0.129259, "evidence_share": 4.5, "evidence_share_display": "4.5", "freshness_pct": 80.8, "age_days": 2.1, "influence_label": "Low", "duplicate_count": 3, "topics": ["Biotech", "Earnings", "Free Cash Flow", "Guidance", "M A", "Operating Income"], "evidence_basis": "", "score_included": true}, {"title": "AstraZeneca stock outlook: Seller pressure limits upside for AZN", "summary": "", "url": "https://news.google.com/rss/articles/CBMimAFBVV95cUxOZThtUFlzWXR2U21QZl9RT0p4OUt4bngtN2lOWWx2Yk81aU5NNGJVTzVSazZQcWF0b0ltbTVIRm40elJRWVQweC1OTHZrUEprNExZek1PcVJRUHkzTW1hdEVnVTBlelV6SDlwOGFNUFhzS0UxY1kxVnljOVhyY084MUN1eEFGVzUyb05fWUZzWlpJMW1FdHJJTA?oc=5", "source_link": "https://news.google.com/rss/articles/CBMimAFBVV95cUxOZThtUFlzWXR2U21QZl9RT0p4OUt4bngtN2lOWWx2Yk81aU5NNGJVTzVSazZQcWF0b0ltbTVIRm40elJRWVQweC1OTHZrUEprNExZek1PcVJRUHkzTW1hdEVnVTBlelV6SDlwOGFNUFhzS0UxY1kxVnljOVhyY084MUN1eEFGVzUyb05fWUZzWlpJMW1FdHJJTA?oc=5", "source_link_is_lookup": false, "source_name": "Traders Union", "published_at": "2026-08-11T08:02:34+00:00", "published_display": "11 Aug 2026 08:02", "provider": "archive", "providers": ["archive", "google_news"], "source_names": ["Traders Union"], "source_kind": "publisher", "story_key": "3223f7b27c42927a965cc07584780903d04231efb65dc1c02a59f699c61d5eb0", "target_scope": "", "durable_archive": false, "archive_provider": "google_news", "sentiment_origin": "stored_reclassified", "model_confidence": 0.461, "provider_directional_mass": null, "relevance_score": 0.78, "entity_mapped": true, "sentiment_conflict": 0.0, "sentiment": "positive", "sentiment_pct": 57, "tone_signals": ["Positive financial language"], "event_type": "guidance", "event_label": "Guidance", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage", "is_stale": false, "evidence_weight": 0.108248, "evidence_share": 3.8, "evidence_share_display": "3.8", "freshness_pct": 79.1, "age_days": 2.4, "influence_label": "Low", "duplicate_count": 2, "topics": [], "evidence_basis": "headline_only", "score_included": true}, {"title": "Jim Cramer Recommends Goldman Sachs and Morgan Stanley to Profit From Accelerating M&A Deals", "summary": "During Mad Money's August 6 episode, host Jim Cramer highlighted why investors should target elite advisory firms rather than speculating on acquisition targets, as he said: Here's a big theme that right now really only impacts two large companies: pent-up demand for mergers and acquisitions now that the Biden era of overzealous antitrust enforcement has been replaced by the Trump era of almost non-existent antitrust enforcement. Most companies don't believe this moment can last, so they're taking advantage of it to make deals. When the summer's over, I believe we're going to come back to see ", "url": "https://finance.yahoo.com/markets/stocks/articles/jim-cramer-recommends-goldman-sachs-054332862.html", "source_link": "https://finance.yahoo.com/markets/stocks/articles/jim-cramer-recommends-goldman-sachs-054332862.html", "source_link_is_lookup": false, "source_name": "finance.yahoo.com", "published_at": "2026-08-11T05:43:32+00:00", "published_display": "11 Aug 2026 05:43", "provider": "eodhd", "providers": ["eodhd"], "source_names": ["finance.yahoo.com"], "source_kind": "aggregator", "story_key": "fe554c1191a7dbcaa26c115af12013eb71f4be342d20eec97d15a6594f5991b9", "target_scope": "", "durable_archive": false, "archive_provider": "", "sentiment_origin": "provider_blend", "model_confidence": 0.669, "provider_directional_mass": 0.156, "relevance_score": 0.78, "entity_mapped": true, "sentiment_conflict": 0.0, "sentiment": "positive", "sentiment_pct": 82, "tone_signals": ["Improving financial comparison"], "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 96, "tier": "direct", "tier_label": "Direct company coverage", "is_stale": false, "evidence_weight": 0.174268, "evidence_share": 6.1, "evidence_share_display": "6.1", "freshness_pct": 78.3, "age_days": 2.5, "influence_label": "Low", "duplicate_count": 3, "topics": ["Earnings", "Earnings Per Share", "Earnings Report", "Financial Results", "Financials", "Fourth Quarter"], "evidence_basis": "", "score_included": true}, {"title": "Can AstraZeneca (AZN) Reach Its $80 Billion Revenue Goal Despite Clinical Setbacks?", "summary": "It was reported on July 27 that AstraZeneca PLC (NASDAQ:AZN) shares outperformed in European trading after the company reported second-quarter earnings that beat Wall Street expectations and reiterated its full-year 2026 guidance. Core earnings per share (EPS) jumped 18% on a constant exchange rate (FXN) basis year-over-year to $2.63, comfortably ahead of the $2.48 analyst consensus. Total revenue reached $15.38 billion, up 5% at constant exchange rates, driven primarily by sustained momentum in its Oncology and Rare Disease units. Management reconfirmed its full-year 2026 outlook of mid-to-hi", "url": "https://finance.yahoo.com/healthcare/articles/astrazeneca-azn-reach-80-billion-234403667.html", "source_link": "https://finance.yahoo.com/healthcare/articles/astrazeneca-azn-reach-80-billion-234403667.html", "source_link_is_lookup": false, "source_name": "finance.yahoo.com", "published_at": "2026-08-10T23:44:03+00:00", "published_display": "10 Aug 2026 23:44", "provider": "eodhd", "providers": ["eodhd"], "source_names": ["finance.yahoo.com"], "source_kind": "aggregator", "story_key": "78c6a1bd2ad031fb0a3c1669ca0cca5e3c1df0cd3854841e10d7280098ea7d9b", "target_scope": "", "durable_archive": false, "archive_provider": "", "sentiment_origin": "provider_blend", "model_confidence": 0.766, "provider_directional_mass": 0.198, "relevance_score": 0.78, "entity_mapped": true, "sentiment_conflict": 0.376, "sentiment": "positive", "sentiment_pct": 76, "tone_signals": ["Beat expectations", "Strong Demand", "Operating deterioration", "Operating growth"], "event_type": "earnings", "event_label": "Earnings", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage", "is_stale": false, "evidence_weight": 0.176388, "evidence_share": 6.2, "evidence_share_display": "6.2", "freshness_pct": 68.6, "age_days": 2.7, "influence_label": "Low", "duplicate_count": 3, "topics": ["Balance Sheet", "Clinical Trials", "Dividends", "Earnings", "Earnings Growth", "Earnings Per Share"], "evidence_basis": "", "score_included": true}, {"title": "Jim Cramer Highlights Pharmaceutical Giants as Non-Tech Innovation Plays Like JNJ and LLY", "summary": "During the August 6 episode of CNBC's Mad Money, Jim Cramer pointed to a growing sector rotation as portfolio managers look for innovation outside the mega-cap technology space. He said: Finally, tech had such a run that portfolio managers want exposure to other sectors of the market that still have innovation. Think of them as non- tech tech stocks. For the\u2026 Charitable Trust club, we've been emphasizing Eli Lilly and Johnson & Johnson. And we talked about these\u2026 I talked about them at length with Jeff Marks today at our 10:20 call. They both had terrific quarters and deserve to be bought on a", "url": "https://finance.yahoo.com/healthcare/articles/jim-cramer-highlights-pharmaceutical-giants-180730894.html", "source_link": "https://finance.yahoo.com/healthcare/articles/jim-cramer-highlights-pharmaceutical-giants-180730894.html", "source_link_is_lookup": false, "source_name": "finance.yahoo.com", "published_at": "2026-08-10T18:07:30+00:00", "published_display": "10 Aug 2026 18:07", "provider": "eodhd", "providers": ["eodhd"], "source_names": ["finance.yahoo.com"], "source_kind": "aggregator", "story_key": "8b0ace502be00ea4bc72828a6487f37dc7a95891208f25bb0d9a938c27f240fa", "target_scope": "", "durable_archive": false, "archive_provider": "", "sentiment_origin": "provider_blend", "model_confidence": 0.614, "provider_directional_mass": 0.214, "relevance_score": 0.78, "entity_mapped": true, "sentiment_conflict": 0.95, "sentiment": "neutral", "sentiment_pct": 55, "tone_signals": ["Deteriorating financial comparison", "Operating growth"], "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage", "is_stale": false, "evidence_weight": 0.088433, "evidence_share": 3.1, "evidence_share_display": "3.1", "freshness_pct": 66.4, "age_days": 3.0, "influence_label": "Low", "duplicate_count": 3, "topics": ["Balance Sheet", "Biotech", "Fda Approval", "Fourth Quarter", "Healthcare", "M A"], "evidence_basis": "", "score_included": true}, {"title": "AstraZeneca PLC (AZN) Stock Analysis: Unveiling a 32% Potential Upside Amid Strong Buy Ratings", "summary": "", "url": "https://news.google.com/rss/articles/CBMi2AFBVV95cUxPbzRBN01Qd280NC1Zenlfdy1ySDNDeDZKU0tFZGx5eDJqS2pOeTJ1YmY0VkdNVHl2NjJsLUl6NzZZRF9Ra1hRWXBJU1lmWnFub0llLTB3ZDZnLTFSa2prTHh0aEdvMTBfUHpuUG9wcFNpaHg0Ml94bGdQMWF5QUlnM210a1lHVVJJSTA5WG15ekFaeFhQNnNiX1VKTWVsVW5uc2UzazNKeFVOQUk5S3dfV1VNODE5QUE0SDZhZ3psbnczWWprSDNMZHBjMFBfTlRHMEdSN2pNZ0w?oc=5", "source_link": "https://news.google.com/rss/articles/CBMi2AFBVV95cUxPbzRBN01Qd280NC1Zenlfdy1ySDNDeDZKU0tFZGx5eDJqS2pOeTJ1YmY0VkdNVHl2NjJsLUl6NzZZRF9Ra1hRWXBJU1lmWnFub0llLTB3ZDZnLTFSa2prTHh0aEdvMTBfUHpuUG9wcFNpaHg0Ml94bGdQMWF5QUlnM210a1lHVVJJSTA5WG15ekFaeFhQNnNiX1VKTWVsVW5uc2UzazNKeFVOQUk5S3dfV1VNODE5QUE0SDZhZ3psbnczWWprSDNMZHBjMFBfTlRHMEdSN2pNZ0w?oc=5", "source_link_is_lookup": false, "source_name": "DirectorsTalk Interviews", "published_at": "2026-08-10T09:20:03+00:00", "published_display": "10 Aug 2026 09:20", "provider": "archive", "providers": ["archive", "google_news"], "source_names": ["DirectorsTalk Interviews"], "source_kind": "publisher", "story_key": "b1759ff7c26a37aabd57329479e9408a68cc0ac5ad951dfdf97bb269f1051d56", "target_scope": "", "durable_archive": false, "archive_provider": "google_news", "sentiment_origin": "stored_reclassified", "model_confidence": 0.493, "provider_directional_mass": null, "relevance_score": 0.78, "entity_mapped": true, "sentiment_conflict": 0.0, "sentiment": "positive", "sentiment_pct": 63, "tone_signals": ["Positive financial language"], "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage", "is_stale": false, "evidence_weight": 0.029139, "evidence_share": 1.0, "evidence_share_display": "1", "freshness_pct": 31.7, "age_days": 3.3, "influence_label": "Low", "duplicate_count": 2, "topics": [], "evidence_basis": "headline_only", "score_included": true}, {"title": "Zimmer Biomet Q2 Earnings Call Highlights", "summary": "Key Points Interested in Zimmer Biomet Holdings, Inc.? Here are five stocks we like better. Zimmer Biomet reported solid Q2 growth: Net sales rose 4.8% to $2.177 billion, driven by hips, specialty businesses and technology. Adjusted EPS was $2.07, while U.S. organic sales increased 4.6%. Technology and hip products led performance: Hip sales grew 5.1%, while technology, data, bone cement and surgical sales surged 21.5%, supported by strong ROSA, TMINI and OrthoGrid adoption. Knee sales were nearly flat, with international weakness\u2014especially in China\u2014offsetting U.S. gains. Zimmer Biomet raised", "url": "https://finance.yahoo.com/healthcare/articles/zimmer-biomet-q2-earnings-call-180350126.html", "source_link": "https://finance.yahoo.com/healthcare/articles/zimmer-biomet-q2-earnings-call-180350126.html", "source_link_is_lookup": false, "source_name": "finance.yahoo.com", "published_at": "2026-08-09T18:03:50+00:00", "published_display": "09 Aug 2026 18:03", "provider": "eodhd", "providers": ["eodhd"], "source_names": ["finance.yahoo.com"], "source_kind": "aggregator", "story_key": "74027870843f0593cb643644b9d6f9fd9fb11f95387d065058d48179815d88bd", "target_scope": "", "durable_archive": false, "archive_provider": "", "sentiment_origin": "stored_reclassified", "model_confidence": 0.78, "provider_directional_mass": null, "relevance_score": 0.78, "entity_mapped": true, "sentiment_conflict": 0.0, "sentiment": "positive", "sentiment_pct": 90, "tone_signals": ["Improving financial comparison", "Operating growth"], "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage", "is_stale": false, "evidence_weight": 0.186901, "evidence_share": 6.6, "evidence_share_display": "6.6", "freshness_pct": 57.8, "age_days": 4.0, "influence_label": "Low", "duplicate_count": 3, "topics": ["Earnings", "Earnings Per Share", "Free Cash Flow", "Growth Rate", "Guidance", "Healthcare"], "evidence_basis": "archived_article", "score_included": true}, {"title": "Notable healthcare headlines for the week: Eli Lilly, Novo Nordisk, and Pfizer in focus", "summary": "Wall Street\u2019s major market averages ended higher on Friday after July's nonfarm payrolls surprised to the downside, showing an unexpected contraction in employment. The blue-chip Dow edged up 0.3%, the benchmark S&P 500 gained 0.62%, and the tech-focused Nasdaq Composite jumped 1.3%. The S&P 500 Health Care Index Sector (XLV [https://seekingalpha.com/symbol/XLV]) gained 1.92% during the week. The top S&P 500 healthcare gainers and losers for the last week are as follows: TOP GAINERS: Charles River Laboratories International (CRL [https://seekingalpha.com/symbol/CRL]) +15.04% Veeva Systems (VEE", "url": "https://seekingalpha.com/news/4629554-notable-healthcare-headlines-for-the-week-eli-lilly-novo-nordisk-and-pfizer-in-focus?amp%3Butm_medium=referral&amp%3Bfeed_item_type=news", "source_link": "https://seekingalpha.com/news/4629554-notable-healthcare-headlines-for-the-week-eli-lilly-novo-nordisk-and-pfizer-in-focus?amp%3Butm_medium=referral&amp%3Bfeed_item_type=news", "source_link_is_lookup": false, "source_name": "seekingalpha.com", "published_at": "2026-08-09T13:05:04+00:00", "published_display": "09 Aug 2026 13:05", "provider": "eodhd", "providers": ["eodhd"], "source_names": ["seekingalpha.com"], "source_kind": "publisher", "story_key": "d57b5b18af87a6c4c97d2c4c28d98cf6f03ef2e7928b939a0fe59ecb5ec288c0", "target_scope": "", "durable_archive": false, "archive_provider": "", "sentiment_origin": "provider_blend", "model_confidence": 0.752, "provider_directional_mass": 0.154, "relevance_score": 0.78, "entity_mapped": true, "sentiment_conflict": 0.445, "sentiment": "positive", "sentiment_pct": 74, "tone_signals": ["Beat expectations", "Guidance raised", "Improving financial comparison", "Operating deterioration"], "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage", "is_stale": false, "evidence_weight": 0.149429, "evidence_share": 5.3, "evidence_share_display": "5.3", "freshness_pct": 56.2, "age_days": 4.2, "influence_label": "Low", "duplicate_count": 3, "topics": ["Consensus Estimate", "Earnings", "Earnings Per Share", "Guidance", "Healthcare", "M A"], "evidence_basis": "", "score_included": true}, {"title": "SA Asks: What's the outlook for Big Pharma M&A?", "summary": "[Medical research with pipette and test tube, DNA analysis, biotechnology, genetic science and healthcare] jittawit.21 Big Pharma moved back into the spotlight last week following a Financial Times report that Bristol Myers Squibb (BMY [https://seekingalpha.com/symbol/BMY]) was in merger talks with AstraZeneca (AZN [https://seekingalpha.com/symbol/AZN]), a development that was later denied by unnamed sources to Reuters. We asked Seeking Alpha analysts Stephen Ayers [https://seekingalpha.com/author/stephen-ayers], ALLKA Research [https://seekingalpha.com/author/allka-research], and Chris DeMuth", "url": "https://seekingalpha.com/news/4629652-sa-asks-whats-the-outlook-for-big-pharma-ma?amp%3Butm_medium=referral&amp%3Bfeed_item_type=news", "source_link": "https://seekingalpha.com/news/4629652-sa-asks-whats-the-outlook-for-big-pharma-ma?amp%3Butm_medium=referral&amp%3Bfeed_item_type=news", "source_link_is_lookup": false, "source_name": "seekingalpha.com", "published_at": "2026-08-08T19:28:35+00:00", "published_display": "08 Aug 2026 19:28", "provider": "eodhd", "providers": ["eodhd"], "source_names": ["seekingalpha.com"], "source_kind": "publisher", "story_key": "fd6f6ddc120c4d3f8b5e3d484fa6bed2d394475902a0ec5eeeefda565db16bfa", "target_scope": "", "durable_archive": false, "archive_provider": "", "sentiment_origin": "provider_blend", "model_confidence": 0.614, "provider_directional_mass": 0.0989, "relevance_score": 0.78, "entity_mapped": true, "sentiment_conflict": 0.0, "sentiment": "negative", "sentiment_pct": 34, "tone_signals": ["Operating deterioration"], "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage", "is_stale": false, "evidence_weight": 0.103605, "evidence_share": 3.6, "evidence_share_display": "3.6", "freshness_pct": 61.6, "age_days": 4.9, "influence_label": "Low", "duplicate_count": 3, "topics": ["Biotech", "Fda Approval", "M A", "M&a", "Oncology", "Pharma"], "evidence_basis": "", "score_included": true}, {"title": "Trending stocks this week as SpaceX, Palantir earnings and jobs data drive markets", "summary": "[Wall Street New York stock exchange stock market] alexsl Wall Street ended the week higher, with the Dow Jones Industrial Average (DJI [https://seekingalpha.com/symbol/DJI]) and the S&P 500 (SP500 [https://seekingalpha.com/symbol/SP500]) closing at record highs as investors weighed a deluge of corporate earnings, including results from SpaceX (SPCX [https://seekingalpha.com/symbol/SPCX]) and Palantir Technologies (PLTR [https://seekingalpha.com/symbol/PLTR]), alongside weaker-than-expected U.S. payrolls data. U.S. nonfarm payrolls fell by 23,000 in July, missing economists' expectations for a", "url": "https://seekingalpha.com/news/4629310-trending-stocks-this-week-as-spacex-palantir-earnings-and-jobs-data-drive-markets?amp%3Butm_medium=referral&amp%3Bfeed_item_type=news", "source_link": "https://seekingalpha.com/news/4629310-trending-stocks-this-week-as-spacex-palantir-earnings-and-jobs-data-drive-markets?amp%3Butm_medium=referral&amp%3Bfeed_item_type=news", "source_link_is_lookup": false, "source_name": "seekingalpha.com", "published_at": "2026-08-08T17:12:36+00:00", "published_display": "08 Aug 2026 17:12", "provider": "eodhd", "providers": ["eodhd"], "source_names": ["seekingalpha.com"], "source_kind": "publisher", "story_key": "3de5b53e39642d63ea3e66b9431f8d6721c947cda34a3c65a2fb2f0d754c1b1a", "target_scope": "", "durable_archive": false, "archive_provider": "", "sentiment_origin": "provider_blend", "model_confidence": 0.77, "provider_directional_mass": 0.132, "relevance_score": 0.78, "entity_mapped": true, "sentiment_conflict": 0.284, "sentiment": "positive", "sentiment_pct": 78, "tone_signals": ["Beat expectations", "Missed expectations", "Guidance raised", "Improving financial comparison"], "event_type": "earnings", "event_label": "Earnings", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage", "is_stale": false, "evidence_weight": 0.145928, "evidence_share": 5.1, "evidence_share_display": "5.1", "freshness_pct": 50.1, "age_days": 5.0, "influence_label": "Low", "duplicate_count": 3, "topics": ["AI", "Consensus Estimate", "Earnings", "Earnings Per Share", "Earnings Report", "Fourth Quarter"], "evidence_basis": "", "score_included": true}, {"title": "AstraZeneca (LSE:AZN) Signs Two Cancer Diagnostics Deals To Widen Patient Access", "summary": "Make better investment decisions with Simply Wall St's easy, visual tools that give you a competitive edge. SOPHiA GENETICS and AstraZeneca (LSE:AZN) have entered a global partnership to develop and launch two decentralized companion diagnostics in precision oncology. The multi-year collaboration focuses on clinical trial assays that support development and commercialization of AstraZeneca's oncology therapies. The partners aim to expand access to personalized cancer treatments by enabling decentralized testing across a wider range of clinical settings. For readers tracking how data driven too", "url": "https://finance.yahoo.com/healthcare/articles/astrazeneca-lse-azn-signs-two-151237153.html", "source_link": "https://finance.yahoo.com/healthcare/articles/astrazeneca-lse-azn-signs-two-151237153.html", "source_link_is_lookup": false, "source_name": "finance.yahoo.com", "published_at": "2026-08-08T15:12:37+00:00", "published_display": "08 Aug 2026 15:12", "provider": "eodhd", "providers": ["eodhd"], "source_names": ["finance.yahoo.com"], "source_kind": "aggregator", "story_key": "2ce674b337483eaa8cdb7407eb2350e4630b953f63dafef1c2bbd3a4558cba28", "target_scope": "", "durable_archive": false, "archive_provider": "", "sentiment_origin": "provider_blend", "model_confidence": 0.614, "provider_directional_mass": 0.123, "relevance_score": 0.795492, "entity_mapped": true, "sentiment_conflict": 0.0, "sentiment": "positive", "sentiment_pct": 72, "tone_signals": ["Operating growth"], "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage", "is_stale": false, "evidence_weight": 0.105893, "evidence_share": 3.7, "evidence_share_display": "3.7", "freshness_pct": 60.5, "age_days": 5.1, "influence_label": "Low", "duplicate_count": 3, "topics": ["Clinical Trials", "Oncology", "Partnership", "Pharma", "Precision Medicine", "Share Price"], "evidence_basis": "", "score_included": true}, {"title": "Parallel Advisors LLC Purchases New Position in Astrazeneca Plc $AZN", "summary": "", "url": "", "source_link": "https://www.google.com/search?tbm=nws&q=%22Parallel+Advisors+LLC+Purchases+New+Position+in+Astrazeneca+Plc+%24AZN%22+%22MarketBeat%22", "source_link_is_lookup": true, "source_name": "MarketBeat", "published_at": "2026-08-08T09:18:55+00:00", "published_display": "08 Aug 2026 09:18", "provider": "archive", "providers": ["archive"], "source_names": ["MarketBeat"], "source_kind": "publisher", "story_key": "f8f0d725171a435f5624cd93b27d5671f39cc3a33ca42d82548265865b563881", "target_scope": "", "durable_archive": true, "archive_provider": "snapshot", "sentiment_origin": "stored_reclassified", "model_confidence": 0.4, "provider_directional_mass": null, "relevance_score": 0.78, "entity_mapped": true, "sentiment_conflict": 0.0, "sentiment": "neutral", "sentiment_pct": 50, "tone_signals": [], "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage", "is_stale": false, "evidence_weight": 0.008467, "evidence_share": 0.3, "evidence_share_display": "0.3", "freshness_pct": 15.8, "age_days": 5.3, "influence_label": "Low", "duplicate_count": 1, "topics": [], "evidence_basis": "headline_only", "score_included": true}, {"title": "Roche Stock Jumps as Morgan Stanley Sees Drug Breakout", "summary": "This article first appeared on GuruFocus. Roche Holding (RHHBY), the Swiss pharmaceutical and diagnostics giant, got a major Wall Street vote of confidence after Morgan Stanley upgraded the stock to Overweight from Equal Weight and hiked its ADR price target to $63 from $46. The upgrade helped send Roche's U.S.-traded ADRs up about 2.2% to $57.38 during Friday's session. Morgan Stanley also swapped out AstraZeneca as its top pharmaceutical pick in favor of Roche, a clear sign the bank believes the company's next growth story is gaining momentum. Warning! GuruFocus has detected 7 Warning Signs ", "url": "https://finance.yahoo.com/healthcare/articles/roche-stock-jumps-morgan-stanley-193033041.html", "source_link": "https://finance.yahoo.com/healthcare/articles/roche-stock-jumps-morgan-stanley-193033041.html", "source_link_is_lookup": false, "source_name": "finance.yahoo.com", "published_at": "2026-08-07T19:30:33+00:00", "published_display": "07 Aug 2026 19:30", "provider": "eodhd", "providers": ["eodhd"], "source_names": ["finance.yahoo.com"], "source_kind": "aggregator", "story_key": "21799ecf8ba147bbea3c70855c16c57934e4ad0655c700526e0bc6df6a621e81", "target_scope": "", "durable_archive": false, "archive_provider": "", "sentiment_origin": "provider_blend", "model_confidence": 0.712, "provider_directional_mass": 0.204, "relevance_score": 0.78, "entity_mapped": true, "sentiment_conflict": 0.291, "sentiment": "positive", "sentiment_pct": 70, "tone_signals": ["Analyst upgrade", "Positive market reaction"], "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage", "is_stale": false, "evidence_weight": 0.044031, "evidence_share": 1.5, "evidence_share_display": "1.5", "freshness_pct": 25.6, "age_days": 5.9, "influence_label": "Low", "duplicate_count": 3, "topics": ["Earnings Estimate", "Fda Approval", "Intrinsic Value", "Pharma", "Price Target"], "evidence_basis": "", "score_included": true}, {"title": "Deal or No Deal, AstraZeneca Stock Is a Bargain", "summary": "", "url": "", "source_link": "https://www.google.com/search?tbm=nws&q=%22Deal+or+No+Deal%2C+AstraZeneca+Stock+Is+a+Bargain%22+%22WSJ%22", "source_link_is_lookup": true, "source_name": "WSJ", "published_at": "2026-08-07T06:39:44.346317+00:00", "published_display": "07 Aug 2026 06:39", "provider": "archive", "providers": ["archive"], "source_names": ["WSJ"], "source_kind": "editorial_wire", "story_key": "b7040788fd8768fddb24b9c72390f17a0e7dc8ee68fc618a665e89ca0c77628c", "target_scope": "", "durable_archive": true, "archive_provider": "snapshot", "sentiment_origin": "stored_reclassified", "model_confidence": 0.4, "provider_directional_mass": null, "relevance_score": 0.78, "entity_mapped": true, "sentiment_conflict": 0.0, "sentiment": "neutral", "sentiment_pct": 50, "tone_signals": [], "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage", "is_stale": false, "evidence_weight": 0.065297, "evidence_share": 2.3, "evidence_share_display": "2.3", "freshness_pct": 52.9, "age_days": 6.4, "influence_label": "Low", "duplicate_count": 1, "topics": [], "evidence_basis": "headline_only", "score_included": true}, {"title": "AstraZeneca Stock Drops 7% as Merger Talks With Bristol Myers Squibb Surface", "summary": "", "url": "", "source_link": "https://www.google.com/search?tbm=nws&q=%22AstraZeneca+Stock+Drops+7%25+as+Merger+Talks+With+Bristol+Myers+Squibb+Surface%22+%22TIKR.com%22", "source_link_is_lookup": true, "source_name": "TIKR.com", "published_at": "2026-08-05T05:39:41.286232+00:00", "published_display": "05 Aug 2026 05:39", "provider": "archive", "providers": ["archive"], "source_names": ["TIKR.com"], "source_kind": "publisher", "story_key": "f7cbab2d0b165c595ba13ddb7ca88d130e5658aa0c244db9e711b6b7ff262fb0", "target_scope": "", "durable_archive": true, "archive_provider": "snapshot", "sentiment_origin": "stored_reclassified", "model_confidence": 0.545, "provider_directional_mass": null, "relevance_score": 0.78, "entity_mapped": true, "sentiment_conflict": 0.0, "sentiment": "negative", "sentiment_pct": 40, "tone_signals": ["Negative market reaction"], "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage", "is_stale": false, "evidence_weight": 0.057072, "evidence_share": 2.0, "evidence_share_display": "2", "freshness_pct": 43.2, "age_days": 8.5, "influence_label": "Low", "duplicate_count": 1, "topics": [], "evidence_basis": "headline_only", "score_included": true}, {"title": "Share price plummets as drugs giant AstraZeneca holds talks over possible merger | ITV News", "summary": "", "url": "https://news.google.com/rss/articles/CBMiwAFBVV95cUxQanBod0VpVmdXTDgwVkpUQU5xZUxnNmRRZm85QVRQVmg3YUhka0c1RkVQVmcxeFJtR1V2Ym1iOXc1UHRGa3g0ek9YRU96YzBQdHIxYXBad2ljb21icDhnN3FCSjA3ZE0xdTdNM1M4NkF6R2dzb0dpWWxMNk1YWHkyMTJqX2NoSWtnRWEtSWlMLVlMNENOb0oxMTBrU0lsLVhKY2ZqY3lpUkxyaEw3RGdEZ1p0MDhtNkNNUU0wQWk0YVM?oc=5", "source_link": "https://news.google.com/rss/articles/CBMiwAFBVV95cUxQanBod0VpVmdXTDgwVkpUQU5xZUxnNmRRZm85QVRQVmg3YUhka0c1RkVQVmcxeFJtR1V2Ym1iOXc1UHRGa3g0ek9YRU96YzBQdHIxYXBad2ljb21icDhnN3FCSjA3ZE0xdTdNM1M4NkF6R2dzb0dpWWxMNk1YWHkyMTJqX2NoSWtnRWEtSWlMLVlMNENOb0oxMTBrU0lsLVhKY2ZqY3lpUkxyaEw3RGdEZ1p0MDhtNkNNUU0wQWk0YVM?oc=5", "source_link_is_lookup": false, "source_name": "ITVX", "published_at": "2026-08-03T07:00:00+00:00", "published_display": "03 Aug 2026 07:00", "provider": "archive", "providers": ["archive", "google_news"], "source_names": ["ITVX"], "source_kind": "publisher", "story_key": "c5dd0ab0f996664b150b125cf7afbf12284430a81a62c96c9570932b7813f9a9", "target_scope": "", "durable_archive": false, "archive_provider": "google_news", "sentiment_origin": "stored_reclassified", "model_confidence": 0.4, "provider_directional_mass": null, "relevance_score": 0.78, "entity_mapped": true, "sentiment_conflict": 0.0, "sentiment": "neutral", "sentiment_pct": 50, "tone_signals": [], "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage", "is_stale": false, "evidence_weight": 0.026402, "evidence_share": 0.9, "evidence_share_display": "0.9", "freshness_pct": 35.7, "age_days": 10.4, "influence_label": "Low", "duplicate_count": 2, "topics": [], "evidence_basis": "headline_only", "score_included": true}, {"title": "AstraZeneca (NYSE:AZN)\u2013Bristol Myers Squibb (NYSE:BMY): Potential $455 Billion Tie-Up Raises Questions Over Deal Value", "summary": "", "url": "", "source_link": "https://www.google.com/search?tbm=nws&q=%22AstraZeneca+%28NYSE%3AAZN%29%E2%80%93Bristol+Myers+Squibb+%28NYSE%3ABMY%29%3A+Potential+%24455+Billion+Tie-Up+Raises+Questions+Over+Deal+Value%22+%22TechStock%C2%B2%22", "source_link_is_lookup": true, "source_name": "TechStock\u00b2", "published_at": "2026-08-03T00:29:47.619070+00:00", "published_display": "03 Aug 2026 00:29", "provider": "archive", "providers": ["archive"], "source_names": ["TechStock\u00b2"], "source_kind": "publisher", "story_key": "104cf3f0fa365dfb739c4b0f734e7c13d30693b9bdacf92e402c01aa6b735152", "target_scope": "", "durable_archive": true, "archive_provider": "snapshot", "sentiment_origin": "stored_reclassified", "model_confidence": 0.461, "provider_directional_mass": null, "relevance_score": 0.78, "entity_mapped": true, "sentiment_conflict": 0.0, "sentiment": "positive", "sentiment_pct": 57, "tone_signals": ["Positive financial language"], "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage", "is_stale": false, "evidence_weight": 0.035639, "evidence_share": 1.3, "evidence_share_display": "1.3", "freshness_pct": 34.7, "age_days": 10.7, "influence_label": "Low", "duplicate_count": 1, "topics": [], "evidence_basis": "headline_only", "score_included": true}, {"title": "AstraZeneca (LSE:AZN) Stock Looks Cheap On Cash Flow While Broader Checks Stay Mixed", "summary": "", "url": "", "source_link": "https://www.google.com/search?tbm=nws&q=%22AstraZeneca+%28LSE%3AAZN%29+Stock+Looks+Cheap+On+Cash+Flow+While+Broader+Checks+Stay+Mixed%22+%22webull.com%22", "source_link_is_lookup": true, "source_name": "webull.com", "published_at": "2026-08-02T18:26:44.950107+00:00", "published_display": "02 Aug 2026 18:26", "provider": "archive", "providers": ["archive"], "source_names": ["webull.com"], "source_kind": "publisher", "story_key": "184700ed63dd2910bc7fbd89427043bd2641da2524bd86dfd4121b4e585c8d70", "target_scope": "", "durable_archive": true, "archive_provider": "snapshot", "sentiment_origin": "stored_reclassified", "model_confidence": 0.4, "provider_directional_mass": null, "relevance_score": 0.78, "entity_mapped": true, "sentiment_conflict": 0.0, "sentiment": "neutral", "sentiment_pct": 50, "tone_signals": [], "event_type": "liquidity", "event_label": "Balance sheet", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage", "is_stale": false, "evidence_weight": 0.032033, "evidence_share": 1.1, "evidence_share_display": "1.1", "freshness_pct": 33.9, "age_days": 10.9, "influence_label": "Low", "duplicate_count": 1, "topics": [], "evidence_basis": "headline_only", "score_included": true}, {"title": "Astrazeneca (AZN) Short Interest & Short Float | Updated Aug 2026 $AZN", "summary": "", "url": "", "source_link": "https://www.google.com/search?tbm=nws&q=%22Astrazeneca+%28AZN%29+Short+Interest+%26+Short+Float+%7C+Updated+Aug+2026+%24AZN%22+%22MarketBeat%22", "source_link_is_lookup": true, "source_name": "MarketBeat", "published_at": "2026-08-02T12:03:08.777546+00:00", "published_display": "02 Aug 2026 12:03", "provider": "archive", "providers": ["archive"], "source_names": ["MarketBeat"], "source_kind": "publisher", "story_key": "1238d136deec8114904410bc053948b1ef868fc2f95cace3e65ecdccff059dd5", "target_scope": "", "durable_archive": true, "archive_provider": "snapshot", "sentiment_origin": "stored_reclassified", "model_confidence": 0.4, "provider_directional_mass": null, "relevance_score": 0.78, "entity_mapped": true, "sentiment_conflict": 0.0, "sentiment": "neutral", "sentiment_pct": 50, "tone_signals": [], "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage", "is_stale": false, "evidence_weight": 0.001101, "evidence_share": 0.0, "evidence_share_display": "<0.1", "freshness_pct": 2.1, "age_days": 11.2, "influence_label": "Low", "duplicate_count": 1, "topics": [], "evidence_basis": "headline_only", "score_included": true}, {"title": "Xencor rises as AstraZeneca royalty row ends (XNCR:NASDAQ)", "summary": "", "url": "", "source_link": "https://www.google.com/search?tbm=nws&q=%22Xencor+rises+as+AstraZeneca+royalty+row+ends+%28XNCR%3ANASDAQ%29%22+%22Seeking+Alpha%22", "source_link_is_lookup": true, "source_name": "Seeking Alpha", "published_at": "2026-07-31T13:52:55.826612+00:00", "published_display": "31 Jul 2026 13:52", "provider": "archive", "providers": ["archive"], "source_names": ["Seeking Alpha"], "source_kind": "publisher", "story_key": "c89b97934a864b9460e5184b6d55257fbb1af99b85d846665651f51bb460bc02", "target_scope": "", "durable_archive": true, "archive_provider": "snapshot", "sentiment_origin": "stored_reclassified", "model_confidence": 0.4, "provider_directional_mass": null, "relevance_score": 0.78, "entity_mapped": true, "sentiment_conflict": 0.0, "sentiment": "neutral", "sentiment_pct": 50, "tone_signals": [], "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage", "is_stale": false, "evidence_weight": 0.00066, "evidence_share": 0.0, "evidence_share_display": "<0.1", "freshness_pct": 1.1, "age_days": 13.1, "influence_label": "Low", "duplicate_count": 1, "topics": [], "evidence_basis": "headline_only", "score_included": true}, {"title": "Fund Update: 42,335 ASTRAZENECA (AZN) shares added to STEPHENS INC |AR| portfolio", "summary": "", "url": "", "source_link": "https://www.google.com/search?tbm=nws&q=%22Fund+Update%3A+42%2C335+ASTRAZENECA+%28AZN%29+shares+added+to+STEPHENS+INC+%7CAR%7C+portfolio%22+%22Quiver+Quantitative%22", "source_link_is_lookup": true, "source_name": "Quiver Quantitative", "published_at": "2026-07-30T06:49:43.156285+00:00", "published_display": "30 Jul 2026 06:49", "provider": "archive", "providers": ["archive"], "source_names": ["Quiver Quantitative"], "source_kind": "publisher", "story_key": "3cbf8f163c6ea5969412c1e8f34af1ab8b1f22efeb01a24df7609eb0dd24588c", "target_scope": "", "durable_archive": true, "archive_provider": "snapshot", "sentiment_origin": "stored_reclassified", "model_confidence": 0.4, "provider_directional_mass": null, "relevance_score": 0.78, "entity_mapped": true, "sentiment_conflict": 0.0, "sentiment": "neutral", "sentiment_pct": 50, "tone_signals": [], "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage", "is_stale": false, "evidence_weight": 0.000361, "evidence_share": 0.0, "evidence_share_display": "<0.1", "freshness_pct": 0.7, "age_days": 14.4, "influence_label": "Low", "duplicate_count": 1, "topics": [], "evidence_basis": "headline_only", "score_included": true}, {"title": "AstraZeneca (AZN) Cash Flow Statement", "summary": "", "url": "", "source_link": "https://www.google.com/search?tbm=nws&q=%22AstraZeneca+%28AZN%29+Cash+Flow+Statement%22+%22Moomoo%22", "source_link_is_lookup": true, "source_name": "Moomoo", "published_at": "2026-07-29T06:59:42.412453+00:00", "published_display": "29 Jul 2026 06:59", "provider": "archive", "providers": ["archive"], "source_names": ["Moomoo"], "source_kind": "publisher", "story_key": "c02832528852856ab5cda0c9d6d4be8d0f9feb77e6f7c8dccd065f3dfa8b6474", "target_scope": "", "durable_archive": true, "archive_provider": "snapshot", "sentiment_origin": "stored_reclassified", "model_confidence": 0.4, "provider_directional_mass": null, "relevance_score": 0.78, "entity_mapped": true, "sentiment_conflict": 0.0, "sentiment": "neutral", "sentiment_pct": 50, "tone_signals": [], "event_type": "liquidity", "event_label": "Balance sheet", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage", "is_stale": false, "evidence_weight": 0.020562, "evidence_share": 0.7, "evidence_share_display": "0.7", "freshness_pct": 21.7, "age_days": 15.4, "influence_label": "Low", "duplicate_count": 1, "topics": [], "evidence_basis": "headline_only", "score_included": true}, {"title": "AstraZeneca (AZN) Earnings Report Anticipated as Wall Street Clo", "summary": "", "url": "", "source_link": "https://www.google.com/search?tbm=nws&q=%22AstraZeneca+%28AZN%29+Earnings+Report+Anticipated+as+Wall+Street+Clo%22+%22GuruFocus%22", "source_link_is_lookup": true, "source_name": "GuruFocus", "published_at": "2026-07-27T00:29:41.681250+00:00", "published_display": "27 Jul 2026 00:29", "provider": "archive", "providers": ["archive"], "source_names": ["GuruFocus"], "source_kind": "publisher", "story_key": "f209ed7e346a9c4787f193ec2fa026c7626fc3fa9a438a975cc7ec66577b9ca6", "target_scope": "", "durable_archive": true, "archive_provider": "snapshot", "sentiment_origin": "stored_reclassified", "model_confidence": 0.4, "provider_directional_mass": null, "relevance_score": 0.78, "entity_mapped": true, "sentiment_conflict": 0.0, "sentiment": "neutral", "sentiment_pct": 50, "tone_signals": [], "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage", "is_stale": false, "evidence_weight": 0.007087, "evidence_share": 0.2, "evidence_share_display": "0.2", "freshness_pct": 8.6, "age_days": 17.7, "influence_label": "Low", "duplicate_count": 1, "topics": [], "evidence_basis": "headline_only", "score_included": true}, {"title": "AstraZeneca PLC (LSE:AZN) Q2 2026: Everything You Need To Know A", "summary": "", "url": "", "source_link": "https://www.google.com/search?tbm=nws&q=%22AstraZeneca+PLC+%28LSE%3AAZN%29+Q2+2026%3A+Everything+You+Need+To+Know+A%22+%22GuruFocus%22", "source_link_is_lookup": true, "source_name": "GuruFocus", "published_at": "2026-07-24T18:40:05.727461+00:00", "published_display": "24 Jul 2026 18:40", "provider": "archive", "providers": ["archive"], "source_names": ["GuruFocus"], "source_kind": "publisher", "story_key": "af7d69a95c503929d563f67c6f92e6a789b78f171e20acfc88b370bdb630505f", "target_scope": "", "durable_archive": true, "archive_provider": "snapshot", "sentiment_origin": "stored_reclassified", "model_confidence": 0.4, "provider_directional_mass": null, "relevance_score": 0.78, "entity_mapped": true, "sentiment_conflict": 0.0, "sentiment": "neutral", "sentiment_pct": 50, "tone_signals": [], "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage", "is_stale": false, "evidence_weight": 5.4e-05, "evidence_share": 0.0, "evidence_share_display": "<0.1", "freshness_pct": 0.1, "age_days": 19.9, "influence_label": "Low", "duplicate_count": 1, "topics": [], "evidence_basis": "headline_only", "score_included": true}, {"title": "AstraZeneca stock forecast: Consolidation near GBX12,547 support", "summary": "", "url": "https://news.google.com/rss/articles/CBMilAFBVV95cUxOaDdDcWgzdFpEalpmOUhvSnc4NGJtN1JZdUFYTzJXb1ZKa2JyaVVQaEI5QVZVTXRka1kzQW9hbWt0M2t5Tm5USFZSM0dRdzE2QVI0cnRQNU8xNmNRR2QxT041ZVEzaXI4amV3d3dEcXNWZXFqbl9YLWNGMzk1WGctY1huWG1pQTJnZ1pWN3hnZEQxQ3Rw?oc=5", "source_link": "https://news.google.com/rss/articles/CBMilAFBVV95cUxOaDdDcWgzdFpEalpmOUhvSnc4NGJtN1JZdUFYTzJXb1ZKa2JyaVVQaEI5QVZVTXRka1kzQW9hbWt0M2t5Tm5USFZSM0dRdzE2QVI0cnRQNU8xNmNRR2QxT041ZVEzaXI4amV3d3dEcXNWZXFqbl9YLWNGMzk1WGctY1huWG1pQTJnZ1pWN3hnZEQxQ3Rw?oc=5", "source_link_is_lookup": false, "source_name": "Traders Union", "published_at": "2026-07-24T07:00:00+00:00", "published_display": "24 Jul 2026 07:00", "provider": "archive", "providers": ["archive", "google_news"], "source_names": ["Traders Union"], "source_kind": "publisher", "story_key": "a51b65c81ced3f58fbfa1ee40c0f3e3570ef05e08598240c3ed5b5e895a0d0f7", "target_scope": "", "durable_archive": false, "archive_provider": "google_news", "sentiment_origin": "stored_reclassified", "model_confidence": 0.4, "provider_directional_mass": null, "relevance_score": 0.78, "entity_mapped": true, "sentiment_conflict": 0.0, "sentiment": "neutral", "sentiment_pct": 50, "tone_signals": [], "event_type": "guidance", "event_label": "Guidance", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage", "is_stale": false, "evidence_weight": 0.013078, "evidence_share": 0.5, "evidence_share_display": "0.5", "freshness_pct": 13.2, "age_days": 20.4, "influence_label": "Low", "duplicate_count": 2, "topics": [], "evidence_basis": "headline_only", "score_included": true}, {"title": "AstraZeneca's (AZN) Etcamah Secures EU Approval for Breast Cance", "summary": "", "url": "", "source_link": "https://www.google.com/search?tbm=nws&q=%22AstraZeneca%27s+%28AZN%29+Etcamah+Secures+EU+Approval+for+Breast+Cance%22+%22GuruFocus%22", "source_link_is_lookup": true, "source_name": "GuruFocus", "published_at": "2026-07-23T12:13:38.006953+00:00", "published_display": "23 Jul 2026 12:13", "provider": "archive", "providers": ["archive"], "source_names": ["GuruFocus"], "source_kind": "publisher", "story_key": "4c6cddc865f18512eabb14944eea2b92420bbbba112fe913e73f90b58a08708f", "target_scope": "", "durable_archive": true, "archive_provider": "snapshot", "sentiment_origin": "stored_reclassified", "model_confidence": 0.564, "provider_directional_mass": null, "relevance_score": 0.78, "entity_mapped": true, "sentiment_conflict": 0.0, "sentiment": "positive", "sentiment_pct": 67, "tone_signals": ["Contract or approval won"], "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage", "is_stale": false, "evidence_weight": 0.024837, "evidence_share": 0.9, "evidence_share_display": "0.9", "freshness_pct": 12.3, "age_days": 21.2, "influence_label": "Low", "duplicate_count": 1, "topics": [], "evidence_basis": "headline_only", "score_included": true}, {"title": "AstraZeneca Stock And 2 Value Picks Trading Below Cash Flow Estimates", "summary": "", "url": "", "source_link": "https://www.google.com/search?tbm=nws&q=%22AstraZeneca+Stock+And+2+Value+Picks+Trading+Below+Cash+Flow+Estimates%22+%22simplywall.st%22", "source_link_is_lookup": true, "source_name": "simplywall.st", "published_at": "2026-07-23T09:01:35.702622+00:00", "published_display": "23 Jul 2026 09:01", "provider": "archive", "providers": ["archive"], "source_names": ["simplywall.st"], "source_kind": "publisher", "story_key": "5829913d42b156c2bb3b7f99cc445b96dd8f471f8c31ecc896a7bed0281459c6", "target_scope": "", "durable_archive": true, "archive_provider": "snapshot", "sentiment_origin": "stored_reclassified", "model_confidence": 0.59, "provider_directional_mass": null, "relevance_score": 0.78, "entity_mapped": true, "sentiment_conflict": 0.0, "sentiment": "negative", "sentiment_pct": 25, "tone_signals": ["Missed expectations"], "event_type": "liquidity", "event_label": "Balance sheet", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage", "is_stale": false, "evidence_weight": 0.029739, "evidence_share": 1.0, "evidence_share_display": "1", "freshness_pct": 12.1, "age_days": 21.3, "influence_label": "Low", "duplicate_count": 1, "topics": [], "evidence_basis": "headline_only", "score_included": true}, {"title": "Astrazeneca (AZN) Falls More Steeply Than Broader Market: What Investors Need to Know", "summary": "", "url": "", "source_link": "https://www.google.com/search?tbm=nws&q=%22Astrazeneca+%28AZN%29+Falls+More+Steeply+Than+Broader+Market%3A+What+Investors+Need+to+Know%22", "source_link_is_lookup": true, "source_name": "Market source", "published_at": "2026-07-21T06:56:14.412373+00:00", "published_display": "21 Jul 2026 06:56", "provider": "archive", "providers": ["archive"], "source_names": ["Market source"], "source_kind": "aggregator", "story_key": "878c5fa1842e86270a0da3b837ab7f104333e48f6cd9e230c242a81d533858bd", "target_scope": "", "durable_archive": true, "archive_provider": "snapshot", "sentiment_origin": "stored_reclassified", "model_confidence": 0.461, "provider_directional_mass": null, "relevance_score": 0.78, "entity_mapped": true, "sentiment_conflict": 0.0, "sentiment": "negative", "sentiment_pct": 43, "tone_signals": ["Negative financial language"], "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage", "is_stale": false, "evidence_weight": 2e-05, "evidence_share": 0.0, "evidence_share_display": "<0.1", "freshness_pct": 0.0, "age_days": 23.4, "influence_label": "Low", "duplicate_count": 1, "topics": [], "evidence_basis": "headline_only", "score_included": true}, {"title": "AstraZeneca needs a shot in the arm to hit $80bn revenue target", "summary": "", "url": "", "source_link": "https://www.google.com/search?tbm=nws&q=%22AstraZeneca+needs+a+shot+in+the+arm+to+hit+%2480bn+revenue+target%22+%22The+Times%22", "source_link_is_lookup": true, "source_name": "The Times", "published_at": "2026-07-20T23:20:50.419575+00:00", "published_display": "20 Jul 2026 23:20", "provider": "archive", "providers": ["archive"], "source_names": ["The Times"], "source_kind": "publisher", "story_key": "7c1af012efbc85f2a39aaa9793ca10b14456bdb428e08ff5b818c72aa556031c", "target_scope": "", "durable_archive": true, "archive_provider": "snapshot", "sentiment_origin": "stored_reclassified", "model_confidence": 0.4, "provider_directional_mass": null, "relevance_score": 0.78, "entity_mapped": true, "sentiment_conflict": 0.0, "sentiment": "neutral", "sentiment_pct": 50, "tone_signals": [], "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage", "is_stale": false, "evidence_weight": 0.003065, "evidence_share": 0.1, "evidence_share_display": "0.1", "freshness_pct": 3.7, "age_days": 23.7, "influence_label": "Low", "duplicate_count": 1, "topics": [], "evidence_basis": "headline_only", "score_included": true}, {"title": "AstraZeneca (AZN) Securities Investigation Notice - Levi & Korsinsky", "summary": "", "url": "", "source_link": "https://www.google.com/search?tbm=nws&q=%22AstraZeneca+%28AZN%29+Securities+Investigation+Notice+-+Levi+%26+Korsinsky%22+%22PR+Newswire%22", "source_link_is_lookup": true, "source_name": "PR Newswire", "published_at": "2026-07-20T16:31:14.351925+00:00", "published_display": "20 Jul 2026 16:31", "provider": "archive", "providers": ["archive"], "source_names": ["PR Newswire"], "source_kind": "press_release", "story_key": "4bdc632a744fe359cf7605677e0bde5a58f34c75798ae0e47cd0e5231c4f38c1", "target_scope": "", "durable_archive": true, "archive_provider": "snapshot", "sentiment_origin": "stored_reclassified", "model_confidence": 0.556, "provider_directional_mass": null, "relevance_score": 0.78, "entity_mapped": true, "sentiment_conflict": 0.0, "sentiment": "negative", "sentiment_pct": 35, "tone_signals": ["Legal or regulatory risk"], "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage", "is_stale": false, "evidence_weight": 0.019867, "evidence_share": 0.7, "evidence_share_display": "0.7", "freshness_pct": 9.3, "age_days": 24.0, "influence_label": "Low", "duplicate_count": 1, "topics": [], "evidence_basis": "headline_only", "score_included": true}, {"title": "AstraZeneca\u2019s Oncology Engine Keeps Running Despite Wainua Setback (NYSE:AZN)", "summary": "", "url": "", "source_link": "https://www.google.com/search?tbm=nws&q=%22AstraZeneca%E2%80%99s+Oncology+Engine+Keeps+Running+Despite+Wainua+Setback+%28NYSE%3AAZN%29%22+%22Seeking+Alpha%22", "source_link_is_lookup": true, "source_name": "Seeking Alpha", "published_at": "2026-07-16T09:29:43.924454+00:00", "published_display": "16 Jul 2026 09:29", "provider": "archive", "providers": ["archive"], "source_names": ["Seeking Alpha"], "source_kind": "publisher", "story_key": "134c541ced90a5ab5b0d1505e14d6d53f9dbe8870590bd85bdc11d0a4a7d6cdf", "target_scope": "", "durable_archive": true, "archive_provider": "snapshot", "sentiment_origin": "stored_reclassified", "model_confidence": 0.4, "provider_directional_mass": null, "relevance_score": 0.78, "entity_mapped": true, "sentiment_conflict": 0.0, "sentiment": "neutral", "sentiment_pct": 50, "tone_signals": [], "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage", "is_stale": false, "evidence_weight": 3e-06, "evidence_share": 0.0, "evidence_share_display": "<0.1", "freshness_pct": 0.0, "age_days": 28.3, "influence_label": "Low", "duplicate_count": 1, "topics": [], "evidence_basis": "headline_only", "score_included": true}], "industry": [], "sector": []}, "total_fetched": 40, "total_unique": 40, "total_relevant": 40, "pipeline_health": {"providers_attempted": 1, "providers_with_results": 1, "provider_counts": {"eodhd": 19}, "raw_articles": 57, "unique_stories": 40, "duplicates_removed": 17, "relevant_stories": 40, "matched_archive_stories": 40, "current_evidence": 40, "direct_evidence": 40, "eodhd_articles": 19, "archive_articles": 21, "eodhd": {"configured": true, "status": "healthy", "calls_used": 425, "call_budget": 500, "budget_used_pct": 85.0, "requests_made": 85, "last_success_at": "2026-08-13T16:46:14.159870+00:00", "newest_seen_at": "2026-08-13T16:33:50+00:00", "rate_limit": 1200, "rate_remaining": 1199, "last_error": "", "mapped_mentions": 3197, "unmapped_mentions": 1970}, "status": "healthy", "durable_evidence_used": true, "durable_collected_at": "2026-08-13T08:09:30.157601+00:00", "durable_newest_article_at": "2026-08-12T13:13:40+00:00", "durable_story_count": 21}, "sentiment_summary": {"positive": 18, "negative": 5, "neutral": 17, "score": 63, "raw_score": 67, "total": 40, "evidence_count": 40, "effective_articles": 21.9, "information_mass": 2.845, "direct_story_count": 40, "direct_source_count": 18, "industry_story_count": 0, "sector_story_count": 0, "story_count": 40, "source_count": 18, "source_concentration": 0.4157, "direct_share": 100, "dispersion": 15, "confidence": 60, "evidence_status": "measured", "score_version": "evidence-v7", "window_days": 30, "weighting_method": "event-aware exponential freshness decay", "newest_article_at": "2026-08-13T15:02:00+00:00", "label": "Constructive news tone", "tone": "positive"}, "classifier": {"primary_event": "earnings", "primary_label": "Earnings", "confidence": 70, "events": [{"event": "earnings", "label": "Earnings", "weight": 6.85, "count": 12}, {"event": "general", "label": "Market update", "weight": 6.1, "count": 10}, {"event": "deals", "label": "Deals and strategy", "weight": 5.6, "count": 9}, {"event": "liquidity", "label": "Balance sheet", "weight": 1.8, "count": 3}, {"event": "regulatory", "label": "Regulatory and legal", "weight": 1.28, "count": 2}, {"event": "guidance", "label": "Guidance", "weight": 1.2, "count": 2}], "positive_events": 18, "negative_events": 5, "pipeline": {"providers_attempted": 1, "providers_with_results": 1, "provider_counts": {"eodhd": 19}, "raw_articles": 57, "unique_stories": 40, "duplicates_removed": 17, "relevant_stories": 40, "matched_archive_stories": 40, "current_evidence": 40, "direct_evidence": 40, "eodhd_articles": 19, "archive_articles": 21, "eodhd": {"configured": true, "status": "healthy", "calls_used": 425, "call_budget": 500, "budget_used_pct": 85.0, "requests_made": 85, "last_success_at": "2026-08-13T16:46:14.159870+00:00", "newest_seen_at": "2026-08-13T16:33:50+00:00", "rate_limit": 1200, "rate_remaining": 1199, "last_error": "", "mapped_mentions": 3197, "unmapped_mentions": 1970}, "status": "healthy", "durable_evidence_used": true, "durable_collected_at": "2026-08-13T08:09:30.157601+00:00", "durable_newest_article_at": "2026-08-12T13:13:40+00:00", "durable_story_count": 21}}, "market_context": {"has_market_context": true, "latest_close": 63825.0, "latest_week": "2026-08-07", "one_week_move": -4.1, "four_week_move": -4.6, "twelve_week_move": -5.2, "trend_signal": "0", "trend_label": "Trend inactive", "trend_tone": "negative", "market_dynamics": -0.715695, "market_dynamics_buy_signal": false, "relative_strength": -17.270173, "fair_value_gap": 55.9, "fair_value_label": "Materially above fair value", "fair_value_tone": "negative", "expectation_direction": "undecided", "expectation_probability": 49.4008, "reaction_label": "Price reacting lower", "reaction_tone": "negative", "market_sentence": "-4.1% over one week, -4.6% over four weeks, trend inactive, and materially above fair value."}, "interpretation": {"label": "Positive news being faded", "tone": "negative", "classification": "positive_rejected", "summary": "Constructive headlines are not being rewarded by price, which raises a rejection flag.", "confidence": 67, "badges": ["Sentiment-trend disagreement", "Positive but stretched"], "opportunities": [], "risks": ["Positive news is arriving while the Sharemaestro trend signal is inactive.", "Constructive tone is arriving with price materially above fair value."], "event_label": "Earnings", "sentiment_word": "constructive"}, "charts": {"sources": [{"label": "finance.yahoo.com", "count": 14}, {"label": "seekingalpha.com", "count": 5}, {"label": "GuruFocus", "count": 3}, {"label": "Traders Union", "count": 2}, {"label": "MarketBeat", "count": 2}, {"label": "Seeking Alpha", "count": 2}, {"label": "DirectorsTalk Interviews", "count": 1}, {"label": "WSJ", "count": 1}], "tiers": [{"label": "Direct company coverage", "count": 40}, {"label": "Industry context", "count": 0}, {"label": "Sector context", "count": 0}], "events": [{"label": "Earnings", "count": 12}, {"label": "Market update", "count": 10}, {"label": "Deals and strategy", "count": 9}, {"label": "Balance sheet", "count": 3}, {"label": "Analyst action", "count": 2}, {"label": "Guidance", "count": 2}, {"label": "Regulatory and legal", "count": 2}]}, "insights": [{"label": "Weighted tone", "value": "63/100", "tone": "positive", "text": "Constructive news tone"}, {"label": "Evidence confidence", "value": "60/100", "tone": "neutral", "text": "21.9 effective stories after overlap and weighting."}, {"label": "Market reaction", "value": "Positive news being faded", "tone": "negative", "text": "Constructive headlines are not being rewarded by price, which raises a rejection flag."}, {"label": "Primary event", "value": "Earnings", "tone": "positive", "text": "70/100 evidence concentration around this catalyst."}, {"label": "Company focus", "value": "40", "tone": "positive", "text": "100% of weighted evidence is company-specific."}, {"label": "Evidence agreement", "value": "15/100", "tone": "positive", "text": "lower dispersion means the independent stories agree more closely."}, {"label": "Trend context", "value": "Trend inactive", "tone": "negative", "text": "-4.1% over one week, -4.6% over four weeks, trend inactive, and materially above fair value."}, {"label": "Latest direct headline", "value": "Positive", "tone": "positive", "text": "The Advertising Research Foundation Announces 2026 ARF David Ogilvy Awards Finalists"}], "updated_at": "2026-08-13T08:09:30.157601+00:00", "detail_intelligence": {"headline": "Constructive news tone", "summary": "The score uses 40 current company stories from 18 publishers.", "status": "measured", "metrics": [{"label": "News score", "value": 63, "display": "63", "tone": "positive", "note": "Constructive news tone"}, {"label": "Confidence", "value": 60, "display": "60", "tone": "neutral", "note": "solid confidence"}, {"label": "Company news", "value": 100, "display": "100%", "tone": "positive", "note": "40 company stories"}, {"label": "Story agreement", "value": 85, "display": "85", "tone": "positive", "note": "15/100 difference"}], "confidence_drivers": [{"label": "Amount of evidence", "value": 57, "note": "2.867 after freshness weighting"}, {"label": "Source breadth", "value": 100, "note": "18 independent publishers"}, {"label": "Company relevance", "value": 100, "note": "share tied directly to this company"}, {"label": "Freshness", "value": 58, "note": "recency-weighted evidence"}, {"label": "Agreement", "value": 85, "note": "how closely stories agree"}, {"label": "Publisher mix", "value": 58, "note": "less reliance on one publisher"}], "freshness": 58, "source_independence": 58, "timeline": [{"date": "2026-07-15", "label": "15 Jul", "count": 0, "score": null, "tone": "neutral", "x": 42.0, "y": 135.0, "volume_height": 0.0, "volume_y": 266.0}, {"date": "2026-07-16", "label": "16 Jul", "count": 1, "score": 50, "tone": "neutral", "x": 73.6, "y": 135.0, "volume_height": 6.5, "volume_y": 259.5}, {"date": "2026-07-17", "label": "17 Jul", "count": 0, "score": null, "tone": "neutral", "x": 105.2, "y": 135.0, "volume_height": 0.0, "volume_y": 266.0}, {"date": "2026-07-18", "label": "18 Jul", "count": 0, "score": null, "tone": "neutral", "x": 136.8, "y": 135.0, "volume_height": 0.0, "volume_y": 266.0}, {"date": "2026-07-19", "label": "19 Jul", "count": 0, "score": null, "tone": "neutral", "x": 168.3, "y": 135.0, "volume_height": 0.0, "volume_y": 266.0}, {"date": "2026-07-20", "label": "20 Jul", "count": 2, "score": 37, "tone": "negative", "x": 199.9, "y": 158.7, "volume_height": 13.0, "volume_y": 253.0}, {"date": "2026-07-21", "label": "21 Jul", "count": 1, "score": 43, "tone": "neutral", "x": 231.5, "y": 147.7, "volume_height": 6.5, "volume_y": 259.5}, {"date": "2026-07-22", "label": "22 Jul", "count": 0, "score": null, "tone": "neutral", "x": 263.1, "y": 135.0, "volume_height": 0.0, "volume_y": 266.0}, {"date": "2026-07-23", "label": "23 Jul", "count": 2, "score": 44, "tone": "neutral", "x": 294.7, "y": 145.9, "volume_height": 13.0, "volume_y": 253.0}, {"date": "2026-07-24", "label": "24 Jul", "count": 2, "score": 50, "tone": "neutral", "x": 326.3, "y": 135.0, "volume_height": 13.0, "volume_y": 253.0}, {"date": "2026-07-25", "label": "25 Jul", "count": 0, "score": null, "tone": "neutral", "x": 357.9, "y": 135.0, "volume_height": 0.0, "volume_y": 266.0}, {"date": "2026-07-26", "label": "26 Jul", "count": 0, "score": null, "tone": "neutral", "x": 389.4, "y": 135.0, "volume_height": 0.0, "volume_y": 266.0}, {"date": "2026-07-27", "label": "27 Jul", "count": 1, "score": 50, "tone": "neutral", "x": 421.0, "y": 135.0, "volume_height": 6.5, "volume_y": 259.5}, {"date": "2026-07-28", "label": "28 Jul", "count": 0, "score": null, "tone": "neutral", "x": 452.6, "y": 135.0, "volume_height": 0.0, "volume_y": 266.0}, {"date": "2026-07-29", "label": "29 Jul", "count": 1, "score": 50, "tone": "neutral", "x": 484.2, "y": 135.0, "volume_height": 6.5, "volume_y": 259.5}, {"date": "2026-07-30", "label": "30 Jul", "count": 1, "score": 50, "tone": "neutral", "x": 515.8, "y": 135.0, "volume_height": 6.5, "volume_y": 259.5}, {"date": "2026-07-31", "label": "31 Jul", "count": 1, "score": 50, "tone": "neutral", "x": 547.4, "y": 135.0, "volume_height": 6.5, "volume_y": 259.5}, {"date": "2026-08-01", "label": "01 Aug", "count": 0, "score": null, "tone": "neutral", "x": 579.0, "y": 135.0, "volume_height": 0.0, "volume_y": 266.0}, {"date": "2026-08-02", "label": "02 Aug", "count": 2, "score": 50, "tone": "neutral", "x": 610.6, "y": 135.0, "volume_height": 13.0, "volume_y": 253.0}, {"date": "2026-08-03", "label": "03 Aug", "count": 2, "score": 54, "tone": "neutral", "x": 642.1, "y": 127.7, "volume_height": 13.0, "volume_y": 253.0}, {"date": "2026-08-04", "label": "04 Aug", "count": 0, "score": null, "tone": "neutral", "x": 673.7, "y": 135.0, "volume_height": 0.0, "volume_y": 266.0}, {"date": "2026-08-05", "label": "05 Aug", "count": 1, "score": 40, "tone": "negative", "x": 705.3, "y": 153.2, "volume_height": 6.5, "volume_y": 259.5}, {"date": "2026-08-06", "label": "06 Aug", "count": 0, "score": null, "tone": "neutral", "x": 736.9, "y": 135.0, "volume_height": 0.0, "volume_y": 266.0}, {"date": "2026-08-07", "label": "07 Aug", "count": 2, "score": 58, "tone": "positive", "x": 768.5, "y": 120.4, "volume_height": 13.0, "volume_y": 253.0}, {"date": "2026-08-08", "label": "08 Aug", "count": 4, "score": 63, "tone": "positive", "x": 800.1, "y": 111.3, "volume_height": 26.0, "volume_y": 240.0}, {"date": "2026-08-09", "label": "09 Aug", "count": 2, "score": 83, "tone": "positive", "x": 831.7, "y": 74.9, "volume_height": 13.0, "volume_y": 253.0}, {"date": "2026-08-10", "label": "10 Aug", "count": 3, "score": 68, "tone": "positive", "x": 863.2, "y": 102.2, "volume_height": 19.5, "volume_y": 246.5}, {"date": "2026-08-11", "label": "11 Aug", "count": 8, "score": 72, "tone": "positive", "x": 894.8, "y": 95.0, "volume_height": 52.0, "volume_y": 214.0}, {"date": "2026-08-12", "label": "12 Aug", "count": 2, "score": 68, "tone": "positive", "x": 926.4, "y": 102.2, "volume_height": 13.0, "volume_y": 253.0}, {"date": "2026-08-13", "label": "13 Aug", "count": 2, "score": 54, "tone": "neutral", "x": 958.0, "y": 127.7, "volume_height": 13.0, "volume_y": 253.0}], "timeline_points": "73.6,135.0 199.9,158.7 231.5,147.7 294.7,145.9 326.3,135.0 421.0,135.0 484.2,135.0 515.8,135.0 547.4,135.0 610.6,135.0 642.1,127.7 705.3,153.2 768.5,120.4 800.1,111.3 831.7,74.9 863.2,102.2 894.8,95.0 926.4,102.2 958.0,127.7", "timeline_has_signal": true, "timeline_start": "15 Jul", "timeline_mid": "30 Jul", "timeline_end": "13 Aug", "momentum": {"label": "Stable", "tone": "neutral", "recent_score": 69, "prior_score": 72, "delta": -3, "recent_count": 14, "prior_count": 8, "volume_delta": 6, "reliable": true, "reliability_note": "Confirmed by at least two stories in both periods"}, "freshness_buckets": [{"label": "Last 24 hours", "count": 2, "share": 5}, {"label": "1 to 3 days", "count": 12, "share": 30}, {"label": "4 to 7 days", "count": 9, "share": 22}, {"label": "8 to 14 days", "count": 6, "share": 15}, {"label": "15 to 21 days", "count": 5, "share": 12}, {"label": "22 to 30 days", "count": 6, "share": 15}], "source_profile": [{"label": "finance.yahoo.com", "count": 14, "share": 35, "score": 72, "tone": "positive"}, {"label": "seekingalpha.com", "count": 5, "share": 12, "score": 69, "tone": "positive"}, {"label": "GuruFocus", "count": 3, "share": 8, "score": 63, "tone": "positive"}, {"label": "Traders Union", "count": 2, "share": 5, "score": 56, "tone": "neutral"}, {"label": "MarketBeat", "count": 2, "share": 5, "score": 50, "tone": "neutral"}, {"label": "Seeking Alpha", "count": 2, "share": 5, "score": 50, "tone": "neutral"}, {"label": "simplywall.st", "count": 1, "share": 2, "score": 25, "tone": "negative"}], "event_profile": [{"label": "Earnings", "count": 12, "share": 30, "score": 74, "tone": "positive"}, {"label": "Market update", "count": 10, "share": 25, "score": 59, "tone": "positive"}, {"label": "Deals and strategy", "count": 9, "share": 22, "score": 60, "tone": "positive"}, {"label": "Balance sheet", "count": 3, "share": 8, "score": 41, "tone": "negative"}, {"label": "Analyst action", "count": 2, "share": 5, "score": 74, "tone": "positive"}, {"label": "Guidance", "count": 2, "share": 5, "score": 56, "tone": "neutral"}, {"label": "Regulatory and legal", "count": 2, "share": 5, "score": 53, "tone": "neutral"}], "topics": [{"label": "Earnings", "count": 9, "share": 22}, {"label": "Earnings Per Share", "count": 7, "share": 18}, {"label": "Oncology", "count": 6, "share": 15}, {"label": "Pharma", "count": 5, "share": 12}, {"label": "M A", "count": 5, "share": 12}, {"label": "Healthcare", "count": 5, "share": 12}, {"label": "Biotech", "count": 4, "share": 10}, {"label": "Guidance", "count": 3, "share": 8}, {"label": "Fourth Quarter", "count": 3, "share": 8}, {"label": "Fda Approval", "count": 3, "share": 8}], "supporting": [{"label": "Direct evidence", "text": "40 current stories are mapped specifically to AZN."}, {"label": "Source breadth", "text": "The read spans 18 publishers rather than depending on one outlet."}, {"label": "Story agreement", "text": "The current stories agree at 85/100."}], "tempering": [{"label": "Price disagreement", "text": "Constructive headlines are not being rewarded by price, which raises a rejection flag."}], "supporting_heading": "What supports the score", "tempering_heading": "What limits the score", "latest_observation": {"title": "The Advertising Research Foundation Announces 2026 ARF David Ogilvy Awards Finalists", "summary": "NEW YORK, Aug. 13, 2026 /PRNewswire/ -- The Advertising Research Foundation (ARF) today announced the finalists for the 2026 ARF David Ogilvy Awards, honoring excellence in research-driven advertising and marketing. For more than 30 years, the ARF David Ogilvy Awards have recognized campaigns that demonstrate how consumer insights and research can inspire creative work that delivers measurable business results. This year's finalists represent leading brands across categories including Automotive, B2B, Cultural Fluency, Financial Services & Insurance, Food & Beverage, Health & Personal Care, Be", "url": "https://finance.yahoo.com/media-advertising/articles/advertising-research-foundation-announces-2026-150200996.html", "source_link": "https://finance.yahoo.com/media-advertising/articles/advertising-research-foundation-announces-2026-150200996.html", "source_link_is_lookup": false, "source_name": "finance.yahoo.com", "published_at": "2026-08-13T15:02:00+00:00", "published_display": "13 Aug 2026 15:02", "source_kind": "aggregator", "sentiment": "positive", "sentiment_pct": 59, "tone_signals": [], "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage", "is_stale": false, "evidence_weight": 0.069369, "evidence_share": 2.4, "evidence_share_display": "2.4", "freshness_pct": 99.7, "age_days": 0.0, "influence_label": "Low", "duplicate_count": 1, "topics": [], "evidence_basis": "", "score_included": true}, "article_count": 40, "updated_at": "2026-08-13T08:09:30.157601+00:00"}, "price_sentiment_path": {"available": true, "price_points": [{"x": 42.0, "y": 95.8, "label": "13 Feb 2026", "close": 75274.45, "index": 100.0}, {"x": 78.4, "y": 103.8, "label": "20 Feb 2026", "close": 74425.0, "index": 98.9}, {"x": 114.9, "y": 86.3, "label": "27 Feb 2026", "close": 76275.0, "index": 101.3}, {"x": 151.3, "y": 125.9, "label": "06 Mar 2026", "close": 72100.0, "index": 95.8}, {"x": 187.7, "y": 145.7, "label": "13 Mar 2026", "close": 70000.0, "index": 93.0}, {"x": 224.2, "y": 169.4, "label": "20 Mar 2026", "close": 67500.0, "index": 89.7}, {"x": 260.6, "y": 148.3, "label": "27 Mar 2026", "close": 69725.0, "index": 92.6}, {"x": 297.0, "y": 102.2, "label": "03 Apr 2026", "close": 74600.0, "index": 99.1}, {"x": 333.5, "y": 94.4, "label": "10 Apr 2026", "close": 75425.0, "index": 100.2}, {"x": 369.9, "y": 98.6, "label": "17 Apr 2026", "close": 74975.0, "index": 99.6}, {"x": 406.3, "y": 137.5, "label": "24 Apr 2026", "close": 70875.0, "index": 94.2}, {"x": 442.8, "y": 140.8, "label": "01 May 2026", "close": 70525.0, "index": 93.7}, {"x": 479.2, "y": 167.0, "label": "08 May 2026", "close": 67750.0, "index": 90.0}, {"x": 515.6, "y": 171.1, "label": "15 May 2026", "close": 67325.0, "index": 89.4}, {"x": 552.0, "y": 147.4, "label": "22 May 2026", "close": 69825.0, "index": 92.8}, {"x": 588.5, "y": 156.6, "label": "29 May 2026", "close": 68850.0, "index": 91.5}, {"x": 624.9, "y": 144.6, "label": "05 Jun 2026", "close": 70125.0, "index": 93.2}, {"x": 661.3, "y": 174.8, "label": "12 Jun 2026", "close": 66925.0, "index": 88.9}, {"x": 697.8, "y": 184.5, "label": "19 Jun 2026", "close": 65900.0, "index": 87.5}, {"x": 734.2, "y": 120.9, "label": "26 Jun 2026", "close": 72625.0, "index": 96.5}, {"x": 770.6, "y": 55.8, "label": "03 Jul 2026", "close": 79499.12, "index": 105.6}, {"x": 807.1, "y": 175.0, "label": "10 Jul 2026", "close": 66903.48, "index": 88.9}, {"x": 843.5, "y": 183.0, "label": "17 Jul 2026", "close": 66058.8, "index": 87.8}, {"x": 879.9, "y": 173.2, "label": "24 Jul 2026", "close": 67102.23, "index": 89.1}, {"x": 916.4, "y": 178.3, "label": "31 Jul 2026", "close": 66555.67, "index": 88.4}, {"x": 952.8, "y": 204.2, "label": "07 Aug 2026", "close": 63825.0, "index": 84.8}], "sentiment_points": [{"at": "2026-06-19T23:59:59.999Z", "date": "2026-06-19", "label": "19 Jun 2026", "score": 51, "tone": "neutral", "raw_score": 54, "confidence": 30, "stories": 5, "close": 65900.0, "price_change": -1.5, "x": 703.0, "y": 128.2, "show_label": true, "label_y": 118.19999999999999}, {"at": "2026-06-26T23:59:59.999Z", "date": "2026-06-26", "label": "26 Jun 2026", "score": 50, "tone": "neutral", "raw_score": 49, "confidence": 27, "stories": 13, "close": 72625.0, "price_change": 10.2, "x": 739.4, "y": 130.0, "show_label": false, "label_y": 120.0}, {"at": "2026-07-03T23:59:59.999Z", "date": "2026-07-03", "label": "03 Jul 2026", "score": 50, "tone": "neutral", "raw_score": 48, "confidence": 23, "stories": 17, "close": 79499.12, "price_change": 9.5, "x": 775.8, "y": 130.0, "show_label": true, "label_y": 120.0}, {"at": "2026-07-10T23:59:59.999Z", "date": "2026-07-10", "label": "10 Jul 2026", "score": 46, "tone": "neutral", "raw_score": 37, "confidence": 32, "stories": 24, "close": 66903.48, "price_change": -15.8, "x": 812.3, "y": 137.4, "show_label": false, "label_y": 127.4}, {"at": "2026-07-17T23:59:59.999Z", "date": "2026-07-17", "label": "17 Jul 2026", "score": 47, "tone": "neutral", "raw_score": 39, "confidence": 28, "stories": 29, "close": 66058.8, "price_change": -1.3, "x": 848.7, "y": 135.5, "show_label": true, "label_y": 125.5}, {"at": "2026-07-24T23:59:59.999Z", "date": "2026-07-24", "label": "24 Jul 2026", "score": 47, "tone": "neutral", "raw_score": 43, "confidence": 38, "stories": 27, "close": 67102.23, "price_change": 1.6, "x": 885.1, "y": 135.5, "show_label": false, "label_y": 125.5}, {"at": "2026-07-31T23:59:59.999Z", "date": "2026-07-31", "label": "31 Jul 2026", "score": 48, "tone": "neutral", "raw_score": 45, "confidence": 31, "stories": 24, "close": 66555.67, "price_change": -0.8, "x": 921.6, "y": 133.7, "show_label": true, "label_y": 123.69999999999999}, {"at": "2026-08-07T23:59:59.999Z", "date": "2026-08-07", "label": "07 Aug 2026", "score": 50, "tone": "neutral", "raw_score": 50, "confidence": 38, "stories": 27, "close": 63825.0, "price_change": -4.1, "x": 958.0, "y": 130.0, "show_label": true, "label_y": 120.0}], "price_path": "42.0,95.8 78.4,103.8 114.9,86.3 151.3,125.9 187.7,145.7 224.2,169.4 260.6,148.3 297.0,102.2 333.5,94.4 369.9,98.6 406.3,137.5 442.8,140.8 479.2,167.0 515.6,171.1 552.0,147.4 588.5,156.6 624.9,144.6 661.3,174.8 697.8,184.5 734.2,120.9 770.6,55.8 807.1,175.0 843.5,183.0 879.9,173.2 916.4,178.3 952.8,204.2", "sentiment_path": "703.0,128.2 739.4,130.0 775.8,130.0 812.3,137.4 848.7,135.5 885.1,135.5 921.6,133.7 958.0,130.0", "score_version": "evidence-v7", "price_change": -15.2, "sentiment_change": -1, "recent_pairs": [{"at": "2026-08-07T23:59:59.999Z", "date": "2026-08-07", "label": "07 Aug 2026", "score": 50, "tone": "neutral", "raw_score": 50, "confidence": 38, "stories": 27, "close": 63825.0, "price_change": -4.1, "x": 958.0, "y": 130.0, "show_label": true, "label_y": 120.0}, {"at": "2026-07-31T23:59:59.999Z", "date": "2026-07-31", "label": "31 Jul 2026", "score": 48, "tone": "neutral", "raw_score": 45, "confidence": 31, "stories": 24, "close": 66555.67, "price_change": -0.8, "x": 921.6, "y": 133.7, "show_label": true, "label_y": 123.69999999999999}, {"at": "2026-07-24T23:59:59.999Z", "date": "2026-07-24", "label": "24 Jul 2026", "score": 47, "tone": "neutral", "raw_score": 43, "confidence": 38, "stories": 27, "close": 67102.23, "price_change": 1.6, "x": 885.1, "y": 135.5, "show_label": false, "label_y": 125.5}, {"at": "2026-07-17T23:59:59.999Z", "date": "2026-07-17", "label": "17 Jul 2026", "score": 47, "tone": "neutral", "raw_score": 39, "confidence": 28, "stories": 29, "close": 66058.8, "price_change": -1.3, "x": 848.7, "y": 135.5, "show_label": true, "label_y": 125.5}, {"at": "2026-07-10T23:59:59.999Z", "date": "2026-07-10", "label": "10 Jul 2026", "score": 46, "tone": "neutral", "raw_score": 37, "confidence": 32, "stories": 24, "close": 66903.48, "price_change": -15.8, "x": 812.3, "y": 137.4, "show_label": false, "label_y": 127.4}, {"at": "2026-07-03T23:59:59.999Z", "date": "2026-07-03", "label": "03 Jul 2026", "score": 50, "tone": "neutral", "raw_score": 48, "confidence": 23, "stories": 17, "close": 79499.12, "price_change": 9.5, "x": 775.8, "y": 130.0, "show_label": true, "label_y": 120.0}, {"at": "2026-06-26T23:59:59.999Z", "date": "2026-06-26", "label": "26 Jun 2026", "score": 50, "tone": "neutral", "raw_score": 49, "confidence": 27, "stories": 13, "close": 72625.0, "price_change": 10.2, "x": 739.4, "y": 130.0, "show_label": false, "label_y": 120.0}, {"at": "2026-06-19T23:59:59.999Z", "date": "2026-06-19", "label": "19 Jun 2026", "score": 51, "tone": "neutral", "raw_score": 54, "confidence": 30, "stories": 5, "close": 65900.0, "price_change": -1.5, "x": 703.0, "y": 128.2, "show_label": true, "label_y": 118.19999999999999}], "reconstructed": true, "latest_close": 63825.0, "start_label": "13 Feb", "mid_label": "15 May", "end_label": "07 Aug", "live_score_version": "evidence-v7", "comparable_to_live": true}, "sentiment_history": [{"label": "18 Jun 23:59", "short_label": "18 Jun", "collected_at": "2026-06-18T23:59:59.999999+00:00", "score": 51, "delta": 1, "score_change": null, "score_change_display": "Start", "confidence_change": null, "article_change": null, "tone": "neutral", "height": 4, "articles": 3, "confidence": 31, "evidence_status": "provisional", "evidence_label": "Provisional", "score_version": "evidence-v7", "reconstructed": true}, {"label": "19 Jun 23:59", "short_label": "19 Jun", "collected_at": "2026-06-19T23:59:59.999999+00:00", "score": 51, "delta": 1, "score_change": 0, "score_change_display": "+0", "confidence_change": -1, "article_change": 2, "tone": "neutral", "height": 4, "articles": 5, "confidence": 30, "evidence_status": "provisional", "evidence_label": "Provisional", "score_version": "evidence-v7", "reconstructed": true}, {"label": "22 Jun 23:59", "short_label": "22 Jun", "collected_at": "2026-06-22T23:59:59.999999+00:00", "score": 51, "delta": 1, "score_change": 0, "score_change_display": "+0", "confidence_change": -5, "article_change": 1, "tone": "neutral", "height": 4, "articles": 6, "confidence": 25, "evidence_status": "provisional", "evidence_label": "Provisional", "score_version": "evidence-v7", "reconstructed": true}, {"label": "23 Jun 23:59", "short_label": "23 Jun", "collected_at": "2026-06-23T23:59:59.999999+00:00", "score": 50, "delta": 0, "score_change": -1, "score_change_display": "-1", "confidence_change": 4, "article_change": 2, "tone": "neutral", "height": 4, "articles": 8, "confidence": 29, "evidence_status": "provisional", "evidence_label": "Provisional", "score_version": "evidence-v7", "reconstructed": true}, {"label": "24 Jun 23:59", "short_label": "24 Jun", "collected_at": "2026-06-24T23:59:59.999999+00:00", "score": 50, "delta": 0, "score_change": 0, "score_change_display": "+0", "confidence_change": -2, "article_change": 1, "tone": "neutral", "height": 4, "articles": 9, "confidence": 27, "evidence_status": "provisional", "evidence_label": "Provisional", "score_version": "evidence-v7", "reconstructed": true}, {"label": "25 Jun 23:59", "short_label": "25 Jun", "collected_at": "2026-06-25T23:59:59.999999+00:00", "score": 50, "delta": 0, "score_change": 0, "score_change_display": "+0", "confidence_change": 0, "article_change": 2, "tone": "neutral", "height": 4, "articles": 11, "confidence": 27, "evidence_status": "provisional", "evidence_label": "Provisional", "score_version": "evidence-v7", "reconstructed": true}, {"label": "26 Jun 23:59", "short_label": "26 Jun", "collected_at": "2026-06-26T23:59:59.999999+00:00", "score": 50, "delta": 0, "score_change": 0, "score_change_display": "+0", "confidence_change": 0, "article_change": 2, "tone": "neutral", "height": 4, "articles": 13, "confidence": 27, "evidence_status": "provisional", "evidence_label": "Provisional", "score_version": "evidence-v7", "reconstructed": true}, {"label": "29 Jun 23:59", "short_label": "29 Jun", "collected_at": "2026-06-29T23:59:59.999999+00:00", "score": 50, "delta": 0, "score_change": 0, "score_change_display": "+0", "confidence_change": -4, "article_change": 1, "tone": "neutral", "height": 4, "articles": 14, "confidence": 23, "evidence_status": "provisional", "evidence_label": "Provisional", "score_version": "evidence-v7", "reconstructed": true}, {"label": "01 Jul 23:59", "short_label": "01 Jul", "collected_at": "2026-07-01T23:59:59.999999+00:00", "score": 50, "delta": 0, "score_change": 0, "score_change_display": "+0", "confidence_change": 1, "article_change": 2, "tone": "neutral", "height": 4, "articles": 16, "confidence": 24, "evidence_status": "provisional", "evidence_label": "Provisional", "score_version": "evidence-v7", "reconstructed": true}, {"label": "03 Jul 23:59", "short_label": "03 Jul", "collected_at": "2026-07-03T23:59:59.999999+00:00", "score": 50, "delta": 0, "score_change": 0, "score_change_display": "+0", "confidence_change": -1, "article_change": 1, "tone": "neutral", "height": 4, "articles": 17, "confidence": 23, "evidence_status": "provisional", "evidence_label": "Provisional", "score_version": "evidence-v7", "reconstructed": true}, {"label": "05 Jul 23:59", "short_label": "05 Jul", "collected_at": "2026-07-05T23:59:59.999999+00:00", "score": 50, "delta": 0, "score_change": 0, "score_change_display": "+0", "confidence_change": 1, "article_change": 1, "tone": "neutral", "height": 4, "articles": 18, "confidence": 24, "evidence_status": "provisional", "evidence_label": "Provisional", "score_version": "evidence-v7", "reconstructed": true}, {"label": "06 Jul 23:59", "short_label": "06 Jul", "collected_at": "2026-07-06T23:59:59.999999+00:00", "score": 50, "delta": 0, "score_change": 0, "score_change_display": "+0", "confidence_change": -1, "article_change": 1, "tone": "neutral", "height": 4, "articles": 19, "confidence": 23, "evidence_status": "provisional", "evidence_label": "Provisional", "score_version": "evidence-v7", "reconstructed": true}, {"label": "08 Jul 23:59", "short_label": "08 Jul", "collected_at": "2026-07-08T23:59:59.999999+00:00", "score": 50, "delta": 0, "score_change": 0, "score_change_display": "+0", "confidence_change": 2, "article_change": 2, "tone": "neutral", "height": 4, "articles": 21, "confidence": 25, "evidence_status": "provisional", "evidence_label": "Provisional", "score_version": "evidence-v7", "reconstructed": true}, {"label": "09 Jul 23:59", "short_label": "09 Jul", "collected_at": "2026-07-09T23:59:59.999999+00:00", "score": 50, "delta": 0, "score_change": 0, "score_change_display": "+0", "confidence_change": 3, "article_change": 2, "tone": "neutral", "height": 4, "articles": 23, "confidence": 28, "evidence_status": "provisional", "evidence_label": "Provisional", "score_version": "evidence-v7", "reconstructed": true}, {"label": "10 Jul 23:59", "short_label": "10 Jul", "collected_at": "2026-07-10T23:59:59.999999+00:00", "score": 46, "delta": -4, "score_change": -4, "score_change_display": "-4", "confidence_change": 4, "article_change": 1, "tone": "neutral", "height": 8, "articles": 24, "confidence": 32, "evidence_status": "provisional", "evidence_label": "Provisional", "score_version": "evidence-v7", "reconstructed": true}, {"label": "12 Jul 23:59", "short_label": "12 Jul", "collected_at": "2026-07-12T23:59:59.999999+00:00", "score": 47, "delta": -3, "score_change": 1, "score_change_display": "+1", "confidence_change": -2, "article_change": 1, "tone": "neutral", "height": 6, "articles": 25, "confidence": 30, "evidence_status": "provisional", "evidence_label": "Provisional", "score_version": "evidence-v7", "reconstructed": true}, {"label": "13 Jul 23:59", "short_label": "13 Jul", "collected_at": "2026-07-13T23:59:59.999999+00:00", "score": 48, "delta": -2, "score_change": 1, "score_change_display": "+1", "confidence_change": 0, "article_change": 2, "tone": "neutral", "height": 4, "articles": 27, "confidence": 30, "evidence_status": "provisional", "evidence_label": "Provisional", "score_version": "evidence-v7", "reconstructed": true}, {"label": "14 Jul 23:59", "short_label": "14 Jul", "collected_at": "2026-07-14T23:59:59.999999+00:00", "score": 46, "delta": -4, "score_change": -2, "score_change_display": "-2", "confidence_change": 3, "article_change": 1, "tone": "neutral", "height": 8, "articles": 28, "confidence": 33, "evidence_status": "provisional", "evidence_label": "Provisional", "score_version": "evidence-v7", "reconstructed": true}, {"label": "16 Jul 23:59", "short_label": "16 Jul", "collected_at": "2026-07-16T23:59:59.999999+00:00", "score": 47, "delta": -3, "score_change": 1, "score_change_display": "+1", "confidence_change": -3, "article_change": 1, "tone": "neutral", "height": 6, "articles": 29, "confidence": 30, "evidence_status": "provisional", "evidence_label": "Provisional", "score_version": "evidence-v7", "reconstructed": true}, {"label": "20 Jul 23:59", "short_label": "20 Jul", "collected_at": "2026-07-20T23:59:59.999999+00:00", "score": 46, "delta": -4, "score_change": -1, "score_change_display": "-1", "confidence_change": 3, "article_change": -3, "tone": "neutral", "height": 8, "articles": 26, "confidence": 33, "evidence_status": "provisional", "evidence_label": "Provisional", "score_version": "evidence-v7", "reconstructed": true}, {"label": "21 Jul 23:59", "short_label": "21 Jul", "collected_at": "2026-07-21T23:59:59.999999+00:00", "score": 46, "delta": -4, "score_change": 0, "score_change_display": "+0", "confidence_change": -1, "article_change": 1, "tone": "neutral", "height": 8, "articles": 27, "confidence": 32, "evidence_status": "provisional", "evidence_label": "Provisional", "score_version": "evidence-v7", "reconstructed": true}, {"label": "23 Jul 23:59", "short_label": "23 Jul", "collected_at": "2026-07-23T23:59:59.999999+00:00", "score": 46, "delta": -4, "score_change": 0, "score_change_display": "+0", "confidence_change": 5, "article_change": -1, "tone": "neutral", "height": 8, "articles": 26, "confidence": 37, "evidence_status": "provisional", "evidence_label": "Provisional", "score_version": "evidence-v7", "reconstructed": true}, {"label": "24 Jul 23:59", "short_label": "24 Jul", "collected_at": "2026-07-24T23:59:59.999999+00:00", "score": 47, "delta": -3, "score_change": 1, "score_change_display": "+1", "confidence_change": 1, "article_change": 1, "tone": "neutral", "height": 6, "articles": 27, "confidence": 38, "evidence_status": "measured", "evidence_label": "Measured", "score_version": "evidence-v7", "reconstructed": true}, {"label": "27 Jul 23:59", "short_label": "27 Jul", "collected_at": "2026-07-27T23:59:59.999999+00:00", "score": 47, "delta": -3, "score_change": 0, "score_change_display": "+0", "confidence_change": -5, "article_change": -3, "tone": "neutral", "height": 6, "articles": 24, "confidence": 33, "evidence_status": "provisional", "evidence_label": "Provisional", "score_version": "evidence-v7", "reconstructed": true}, {"label": "29 Jul 23:59", "short_label": "29 Jul", "collected_at": "2026-07-29T23:59:59.999999+00:00", "score": 48, "delta": -2, "score_change": 1, "score_change_display": "+1", "confidence_change": -1, "article_change": 0, "tone": "neutral", "height": 4, "articles": 24, "confidence": 32, "evidence_status": "provisional", "evidence_label": "Provisional", "score_version": "evidence-v7", "reconstructed": true}, {"label": "30 Jul 23:59", "short_label": "30 Jul", "collected_at": "2026-07-30T23:59:59.999999+00:00", "score": 48, "delta": -2, "score_change": 0, "score_change_display": "+0", "confidence_change": -1, "article_change": 1, "tone": "neutral", "height": 4, "articles": 25, "confidence": 31, "evidence_status": "provisional", "evidence_label": "Provisional", "score_version": "evidence-v7", "reconstructed": true}, {"label": "31 Jul 23:59", "short_label": "31 Jul", "collected_at": "2026-07-31T23:59:59.999999+00:00", "score": 48, "delta": -2, "score_change": 0, "score_change_display": "+0", "confidence_change": 0, "article_change": -1, "tone": "neutral", "height": 4, "articles": 24, "confidence": 31, "evidence_status": "provisional", "evidence_label": "Provisional", "score_version": "evidence-v7", "reconstructed": true}, {"label": "02 Aug 23:59", "short_label": "02 Aug", "collected_at": "2026-08-02T23:59:59.999999+00:00", "score": 48, "delta": -2, "score_change": 0, "score_change_display": "+0", "confidence_change": 0, "article_change": 1, "tone": "neutral", "height": 4, "articles": 25, "confidence": 31, "evidence_status": "provisional", "evidence_label": "Provisional", "score_version": "evidence-v7", "reconstructed": true}, {"label": "03 Aug 23:59", "short_label": "03 Aug", "collected_at": "2026-08-03T23:59:59.999999+00:00", "score": 49, "delta": -1, "score_change": 1, "score_change_display": "+1", "confidence_change": 2, "article_change": 2, "tone": "neutral", "height": 4, "articles": 27, "confidence": 33, "evidence_status": "provisional", "evidence_label": "Provisional", "score_version": "evidence-v7", "reconstructed": true}, {"label": "05 Aug 23:59", "short_label": "05 Aug", "collected_at": "2026-08-05T23:59:59.999999+00:00", "score": 48, "delta": -2, "score_change": -1, "score_change_display": "-1", "confidence_change": -1, "article_change": -1, "tone": "neutral", "height": 4, "articles": 26, "confidence": 32, "evidence_status": "provisional", "evidence_label": "Provisional", "score_version": "evidence-v7", "reconstructed": true}, {"label": "07 Aug 23:59", "short_label": "07 Aug", "collected_at": "2026-08-07T23:59:59.999999+00:00", "score": 50, "delta": 0, "score_change": 2, "score_change_display": "+2", "confidence_change": 6, "article_change": 1, "tone": "neutral", "height": 4, "articles": 27, "confidence": 38, "evidence_status": "measured", "evidence_label": "Measured", "score_version": "evidence-v7", "reconstructed": true}, {"label": "08 Aug 23:59", "short_label": "08 Aug", "collected_at": "2026-08-08T23:59:59.999999+00:00", "score": 50, "delta": 0, "score_change": 0, "score_change_display": "+0", "confidence_change": 2, "article_change": 2, "tone": "neutral", "height": 4, "articles": 29, "confidence": 40, "evidence_status": "measured", "evidence_label": "Measured", "score_version": "evidence-v7", "reconstructed": true}, {"label": "09 Aug 23:59", "short_label": "09 Aug", "collected_at": "2026-08-09T23:59:59.999999+00:00", "score": 55, "delta": 5, "score_change": 5, "score_change_display": "+5", "confidence_change": 3, "article_change": 1, "tone": "neutral", "height": 10, "articles": 30, "confidence": 43, "evidence_status": "measured", "evidence_label": "Measured", "score_version": "evidence-v7", "reconstructed": true}, {"label": "10 Aug 23:59", "short_label": "10 Aug", "collected_at": "2026-08-10T23:59:59.999999+00:00", "score": 58, "delta": 8, "score_change": 3, "score_change_display": "+3", "confidence_change": 2, "article_change": 3, "tone": "positive", "height": 16, "articles": 33, "confidence": 45, "evidence_status": "measured", "evidence_label": "Measured", "score_version": "evidence-v7", "reconstructed": true}, {"label": "11 Aug 23:59", "short_label": "11 Aug", "collected_at": "2026-08-11T23:59:59.999999+00:00", "score": 58, "delta": 8, "score_change": 0, "score_change_display": "+0", "confidence_change": 7, "article_change": 7, "tone": "positive", "height": 16, "articles": 40, "confidence": 52, "evidence_status": "measured", "evidence_label": "Measured", "score_version": "evidence-v7", "reconstructed": true}, {"label": "12 Aug 23:59", "short_label": "12 Aug", "collected_at": "2026-08-12T23:59:59.999999+00:00", "score": 58, "delta": 8, "score_change": 0, "score_change_display": "+0", "confidence_change": -2, "article_change": 0, "tone": "positive", "height": 16, "articles": 40, "confidence": 50, "evidence_status": "measured", "evidence_label": "Measured", "score_version": "evidence-v7", "reconstructed": true}, {"label": "13 Aug 15:34", "short_label": "13 Aug", "collected_at": "2026-08-13T15:34:45.144072+00:00", "score": 58, "delta": 8, "score_change": 0, "score_change_display": "+0", "confidence_change": 0, "article_change": 1, "tone": "positive", "height": 16, "articles": 41, "confidence": 50, "evidence_status": "measured", "evidence_label": "Measured", "score_version": "evidence-v7", "reconstructed": true}], "sentiment_history_insight": {"available": true, "series_version": "evidence-v7", "live_version": "evidence-v7", "comparable_to_live": true, "reconstructed": true, "observations": 37, "span_label": "56 days", "first_score": 51, "latest_score": 58, "net_change": 7, "net_change_display": "+7", "direction": "Strengthening", "high_score": 58, "low_score": 46, "latest_confidence": 50, "confidence_change": 19, "latest_articles": 41, "article_change": 38, "latest_label": "13 Aug 15:34", "latest_evidence_label": "Measured", "chart_rows": [{"label": "18 Jun 23:59", "short_label": "18 Jun", "collected_at": "2026-06-18T23:59:59.999999+00:00", "score": 51, "delta": 1, "score_change": null, "score_change_display": "Start", "confidence_change": null, "article_change": null, "tone": "neutral", "height": 4, "articles": 3, "confidence": 31, "evidence_status": "provisional", "evidence_label": "Provisional", "score_version": "evidence-v7", "reconstructed": true, "x": 42.0, "y": 133.2}, {"label": "19 Jun 23:59", "short_label": "19 Jun", "collected_at": "2026-06-19T23:59:59.999999+00:00", "score": 51, "delta": 1, "score_change": 0, "score_change_display": "+0", "confidence_change": -1, "article_change": 2, "tone": "neutral", "height": 4, "articles": 5, "confidence": 30, "evidence_status": "provisional", "evidence_label": "Provisional", "score_version": "evidence-v7", "reconstructed": true, "x": 67.4, "y": 133.2}, {"label": "22 Jun 23:59", "short_label": "22 Jun", "collected_at": "2026-06-22T23:59:59.999999+00:00", "score": 51, "delta": 1, "score_change": 0, "score_change_display": "+0", "confidence_change": -5, "article_change": 1, "tone": "neutral", "height": 4, "articles": 6, "confidence": 25, "evidence_status": "provisional", "evidence_label": "Provisional", "score_version": "evidence-v7", "reconstructed": true, "x": 92.9, "y": 133.2}, {"label": "23 Jun 23:59", "short_label": "23 Jun", "collected_at": "2026-06-23T23:59:59.999999+00:00", "score": 50, "delta": 0, "score_change": -1, "score_change_display": "-1", "confidence_change": 4, "article_change": 2, "tone": "neutral", "height": 4, "articles": 8, "confidence": 29, "evidence_status": "provisional", "evidence_label": "Provisional", "score_version": "evidence-v7", "reconstructed": true, "x": 118.3, "y": 135.0}, {"label": "24 Jun 23:59", "short_label": "24 Jun", "collected_at": "2026-06-24T23:59:59.999999+00:00", "score": 50, "delta": 0, "score_change": 0, "score_change_display": "+0", "confidence_change": -2, "article_change": 1, "tone": "neutral", "height": 4, "articles": 9, "confidence": 27, "evidence_status": "provisional", "evidence_label": "Provisional", "score_version": "evidence-v7", "reconstructed": true, "x": 143.8, "y": 135.0}, {"label": "25 Jun 23:59", "short_label": "25 Jun", "collected_at": "2026-06-25T23:59:59.999999+00:00", "score": 50, "delta": 0, "score_change": 0, "score_change_display": "+0", "confidence_change": 0, "article_change": 2, "tone": "neutral", "height": 4, "articles": 11, "confidence": 27, "evidence_status": "provisional", "evidence_label": "Provisional", "score_version": "evidence-v7", "reconstructed": true, "x": 169.2, "y": 135.0}, {"label": "26 Jun 23:59", "short_label": "26 Jun", "collected_at": "2026-06-26T23:59:59.999999+00:00", "score": 50, "delta": 0, "score_change": 0, "score_change_display": "+0", "confidence_change": 0, "article_change": 2, "tone": "neutral", "height": 4, "articles": 13, "confidence": 27, "evidence_status": "provisional", "evidence_label": "Provisional", "score_version": "evidence-v7", "reconstructed": true, "x": 194.7, "y": 135.0}, {"label": "29 Jun 23:59", "short_label": "29 Jun", "collected_at": "2026-06-29T23:59:59.999999+00:00", "score": 50, "delta": 0, "score_change": 0, "score_change_display": "+0", "confidence_change": -4, "article_change": 1, "tone": "neutral", "height": 4, "articles": 14, "confidence": 23, "evidence_status": "provisional", "evidence_label": "Provisional", "score_version": "evidence-v7", "reconstructed": true, "x": 220.1, "y": 135.0}, {"label": "01 Jul 23:59", "short_label": "01 Jul", "collected_at": "2026-07-01T23:59:59.999999+00:00", "score": 50, "delta": 0, "score_change": 0, "score_change_display": "+0", "confidence_change": 1, "article_change": 2, "tone": "neutral", "height": 4, "articles": 16, "confidence": 24, "evidence_status": "provisional", "evidence_label": "Provisional", "score_version": "evidence-v7", "reconstructed": true, "x": 245.6, "y": 135.0}, {"label": "03 Jul 23:59", "short_label": "03 Jul", "collected_at": "2026-07-03T23:59:59.999999+00:00", "score": 50, "delta": 0, "score_change": 0, "score_change_display": "+0", "confidence_change": -1, "article_change": 1, "tone": "neutral", "height": 4, "articles": 17, "confidence": 23, "evidence_status": "provisional", "evidence_label": "Provisional", "score_version": "evidence-v7", "reconstructed": true, "x": 271.0, "y": 135.0}, {"label": "05 Jul 23:59", "short_label": "05 Jul", "collected_at": "2026-07-05T23:59:59.999999+00:00", "score": 50, "delta": 0, "score_change": 0, "score_change_display": "+0", "confidence_change": 1, "article_change": 1, "tone": "neutral", "height": 4, "articles": 18, "confidence": 24, "evidence_status": "provisional", "evidence_label": "Provisional", "score_version": "evidence-v7", "reconstructed": true, "x": 296.4, "y": 135.0}, {"label": "06 Jul 23:59", "short_label": "06 Jul", "collected_at": "2026-07-06T23:59:59.999999+00:00", "score": 50, "delta": 0, "score_change": 0, "score_change_display": "+0", "confidence_change": -1, "article_change": 1, "tone": "neutral", "height": 4, "articles": 19, "confidence": 23, "evidence_status": "provisional", "evidence_label": "Provisional", "score_version": "evidence-v7", "reconstructed": true, "x": 321.9, "y": 135.0}, {"label": "08 Jul 23:59", "short_label": "08 Jul", "collected_at": "2026-07-08T23:59:59.999999+00:00", "score": 50, "delta": 0, "score_change": 0, "score_change_display": "+0", "confidence_change": 2, "article_change": 2, "tone": "neutral", "height": 4, "articles": 21, "confidence": 25, "evidence_status": "provisional", "evidence_label": "Provisional", "score_version": "evidence-v7", "reconstructed": true, "x": 347.3, "y": 135.0}, {"label": "09 Jul 23:59", "short_label": "09 Jul", "collected_at": "2026-07-09T23:59:59.999999+00:00", "score": 50, "delta": 0, "score_change": 0, "score_change_display": "+0", "confidence_change": 3, "article_change": 2, "tone": "neutral", "height": 4, "articles": 23, "confidence": 28, "evidence_status": "provisional", "evidence_label": "Provisional", "score_version": "evidence-v7", "reconstructed": true, "x": 372.8, "y": 135.0}, {"label": "10 Jul 23:59", "short_label": "10 Jul", "collected_at": "2026-07-10T23:59:59.999999+00:00", "score": 46, "delta": -4, "score_change": -4, "score_change_display": "-4", "confidence_change": 4, "article_change": 1, "tone": "neutral", "height": 8, "articles": 24, "confidence": 32, "evidence_status": "provisional", "evidence_label": "Provisional", "score_version": "evidence-v7", "reconstructed": true, "x": 398.2, "y": 142.3}, {"label": "12 Jul 23:59", "short_label": "12 Jul", "collected_at": "2026-07-12T23:59:59.999999+00:00", "score": 47, "delta": -3, "score_change": 1, "score_change_display": "+1", "confidence_change": -2, "article_change": 1, "tone": "neutral", "height": 6, "articles": 25, "confidence": 30, "evidence_status": "provisional", "evidence_label": "Provisional", "score_version": "evidence-v7", "reconstructed": true, "x": 423.7, "y": 140.5}, {"label": "13 Jul 23:59", "short_label": "13 Jul", "collected_at": "2026-07-13T23:59:59.999999+00:00", "score": 48, "delta": -2, "score_change": 1, "score_change_display": "+1", "confidence_change": 0, "article_change": 2, "tone": "neutral", "height": 4, "articles": 27, "confidence": 30, "evidence_status": "provisional", "evidence_label": "Provisional", "score_version": "evidence-v7", "reconstructed": true, "x": 449.1, "y": 138.6}, {"label": "14 Jul 23:59", "short_label": "14 Jul", "collected_at": "2026-07-14T23:59:59.999999+00:00", "score": 46, "delta": -4, "score_change": -2, "score_change_display": "-2", "confidence_change": 3, "article_change": 1, "tone": "neutral", "height": 8, "articles": 28, "confidence": 33, "evidence_status": "provisional", "evidence_label": "Provisional", "score_version": "evidence-v7", "reconstructed": true, "x": 474.6, "y": 142.3}, {"label": "16 Jul 23:59", "short_label": "16 Jul", "collected_at": "2026-07-16T23:59:59.999999+00:00", "score": 47, "delta": -3, "score_change": 1, "score_change_display": "+1", "confidence_change": -3, "article_change": 1, "tone": "neutral", "height": 6, "articles": 29, "confidence": 30, "evidence_status": "provisional", "evidence_label": "Provisional", "score_version": "evidence-v7", "reconstructed": true, "x": 500.0, "y": 140.5}, {"label": "20 Jul 23:59", "short_label": "20 Jul", "collected_at": "2026-07-20T23:59:59.999999+00:00", "score": 46, "delta": -4, "score_change": -1, "score_change_display": "-1", "confidence_change": 3, "article_change": -3, "tone": "neutral", "height": 8, "articles": 26, "confidence": 33, "evidence_status": "provisional", "evidence_label": "Provisional", "score_version": "evidence-v7", "reconstructed": true, "x": 525.4, "y": 142.3}, {"label": "21 Jul 23:59", "short_label": "21 Jul", "collected_at": "2026-07-21T23:59:59.999999+00:00", "score": 46, "delta": -4, "score_change": 0, "score_change_display": "+0", "confidence_change": -1, "article_change": 1, "tone": "neutral", "height": 8, "articles": 27, "confidence": 32, "evidence_status": "provisional", "evidence_label": "Provisional", "score_version": "evidence-v7", "reconstructed": true, "x": 550.9, "y": 142.3}, {"label": "23 Jul 23:59", "short_label": "23 Jul", "collected_at": "2026-07-23T23:59:59.999999+00:00", "score": 46, "delta": -4, "score_change": 0, "score_change_display": "+0", "confidence_change": 5, "article_change": -1, "tone": "neutral", "height": 8, "articles": 26, "confidence": 37, "evidence_status": "provisional", "evidence_label": "Provisional", "score_version": "evidence-v7", "reconstructed": true, "x": 576.3, "y": 142.3}, {"label": "24 Jul 23:59", "short_label": "24 Jul", "collected_at": "2026-07-24T23:59:59.999999+00:00", "score": 47, "delta": -3, "score_change": 1, "score_change_display": "+1", "confidence_change": 1, "article_change": 1, "tone": "neutral", "height": 6, "articles": 27, "confidence": 38, "evidence_status": "measured", "evidence_label": "Measured", "score_version": "evidence-v7", "reconstructed": true, "x": 601.8, "y": 140.5}, {"label": "27 Jul 23:59", "short_label": "27 Jul", "collected_at": "2026-07-27T23:59:59.999999+00:00", "score": 47, "delta": -3, "score_change": 0, "score_change_display": "+0", "confidence_change": -5, "article_change": -3, "tone": "neutral", "height": 6, "articles": 24, "confidence": 33, "evidence_status": "provisional", "evidence_label": "Provisional", "score_version": "evidence-v7", "reconstructed": true, "x": 627.2, "y": 140.5}, {"label": "29 Jul 23:59", "short_label": "29 Jul", "collected_at": "2026-07-29T23:59:59.999999+00:00", "score": 48, "delta": -2, "score_change": 1, "score_change_display": "+1", "confidence_change": -1, "article_change": 0, "tone": "neutral", "height": 4, "articles": 24, "confidence": 32, "evidence_status": "provisional", "evidence_label": "Provisional", "score_version": "evidence-v7", "reconstructed": true, "x": 652.7, "y": 138.6}, {"label": "30 Jul 23:59", "short_label": "30 Jul", "collected_at": "2026-07-30T23:59:59.999999+00:00", "score": 48, "delta": -2, "score_change": 0, "score_change_display": "+0", "confidence_change": -1, "article_change": 1, "tone": "neutral", "height": 4, "articles": 25, "confidence": 31, "evidence_status": "provisional", "evidence_label": "Provisional", "score_version": "evidence-v7", "reconstructed": true, "x": 678.1, "y": 138.6}, {"label": "31 Jul 23:59", "short_label": "31 Jul", "collected_at": "2026-07-31T23:59:59.999999+00:00", "score": 48, "delta": -2, "score_change": 0, "score_change_display": "+0", "confidence_change": 0, "article_change": -1, "tone": "neutral", "height": 4, "articles": 24, "confidence": 31, "evidence_status": "provisional", "evidence_label": "Provisional", "score_version": "evidence-v7", "reconstructed": true, "x": 703.6, "y": 138.6}, {"label": "02 Aug 23:59", "short_label": "02 Aug", "collected_at": "2026-08-02T23:59:59.999999+00:00", "score": 48, "delta": -2, "score_change": 0, "score_change_display": "+0", "confidence_change": 0, "article_change": 1, "tone": "neutral", "height": 4, "articles": 25, "confidence": 31, "evidence_status": "provisional", "evidence_label": "Provisional", "score_version": "evidence-v7", "reconstructed": true, "x": 729.0, "y": 138.6}, {"label": "03 Aug 23:59", "short_label": "03 Aug", "collected_at": "2026-08-03T23:59:59.999999+00:00", "score": 49, "delta": -1, "score_change": 1, "score_change_display": "+1", "confidence_change": 2, "article_change": 2, "tone": "neutral", "height": 4, "articles": 27, "confidence": 33, "evidence_status": "provisional", "evidence_label": "Provisional", "score_version": "evidence-v7", "reconstructed": true, "x": 754.4, "y": 136.8}, {"label": "05 Aug 23:59", "short_label": "05 Aug", "collected_at": "2026-08-05T23:59:59.999999+00:00", "score": 48, "delta": -2, "score_change": -1, "score_change_display": "-1", "confidence_change": -1, "article_change": -1, "tone": "neutral", "height": 4, "articles": 26, "confidence": 32, "evidence_status": "provisional", "evidence_label": "Provisional", "score_version": "evidence-v7", "reconstructed": true, "x": 779.9, "y": 138.6}, {"label": "07 Aug 23:59", "short_label": "07 Aug", "collected_at": "2026-08-07T23:59:59.999999+00:00", "score": 50, "delta": 0, "score_change": 2, "score_change_display": "+2", "confidence_change": 6, "article_change": 1, "tone": "neutral", "height": 4, "articles": 27, "confidence": 38, "evidence_status": "measured", "evidence_label": "Measured", "score_version": "evidence-v7", "reconstructed": true, "x": 805.3, "y": 135.0}, {"label": "08 Aug 23:59", "short_label": "08 Aug", "collected_at": "2026-08-08T23:59:59.999999+00:00", "score": 50, "delta": 0, "score_change": 0, "score_change_display": "+0", "confidence_change": 2, "article_change": 2, "tone": "neutral", "height": 4, "articles": 29, "confidence": 40, "evidence_status": "measured", "evidence_label": "Measured", "score_version": "evidence-v7", "reconstructed": true, "x": 830.8, "y": 135.0}, {"label": "09 Aug 23:59", "short_label": "09 Aug", "collected_at": "2026-08-09T23:59:59.999999+00:00", "score": 55, "delta": 5, "score_change": 5, "score_change_display": "+5", "confidence_change": 3, "article_change": 1, "tone": "neutral", "height": 10, "articles": 30, "confidence": 43, "evidence_status": "measured", "evidence_label": "Measured", "score_version": "evidence-v7", "reconstructed": true, "x": 856.2, "y": 125.9}, {"label": "10 Aug 23:59", "short_label": "10 Aug", "collected_at": "2026-08-10T23:59:59.999999+00:00", "score": 58, "delta": 8, "score_change": 3, "score_change_display": "+3", "confidence_change": 2, "article_change": 3, "tone": "positive", "height": 16, "articles": 33, "confidence": 45, "evidence_status": "measured", "evidence_label": "Measured", "score_version": "evidence-v7", "reconstructed": true, "x": 881.7, "y": 120.4}, {"label": "11 Aug 23:59", "short_label": "11 Aug", "collected_at": "2026-08-11T23:59:59.999999+00:00", "score": 58, "delta": 8, "score_change": 0, "score_change_display": "+0", "confidence_change": 7, "article_change": 7, "tone": "positive", "height": 16, "articles": 40, "confidence": 52, "evidence_status": "measured", "evidence_label": "Measured", "score_version": "evidence-v7", "reconstructed": true, "x": 907.1, "y": 120.4}, {"label": "12 Aug 23:59", "short_label": "12 Aug", "collected_at": "2026-08-12T23:59:59.999999+00:00", "score": 58, "delta": 8, "score_change": 0, "score_change_display": "+0", "confidence_change": -2, "article_change": 0, "tone": "positive", "height": 16, "articles": 40, "confidence": 50, "evidence_status": "measured", "evidence_label": "Measured", "score_version": "evidence-v7", "reconstructed": true, "x": 932.6, "y": 120.4}, {"label": "13 Aug 15:34", "short_label": "13 Aug", "collected_at": "2026-08-13T15:34:45.144072+00:00", "score": 58, "delta": 8, "score_change": 0, "score_change_display": "+0", "confidence_change": 0, "article_change": 1, "tone": "positive", "height": 16, "articles": 41, "confidence": 50, "evidence_status": "measured", "evidence_label": "Measured", "score_version": "evidence-v7", "reconstructed": true, "x": 958.0, "y": 120.4}], "chart_points": "42.0,133.2 67.4,133.2 92.9,133.2 118.3,135.0 143.8,135.0 169.2,135.0 194.7,135.0 220.1,135.0 245.6,135.0 271.0,135.0 296.4,135.0 321.9,135.0 347.3,135.0 372.8,135.0 398.2,142.3 423.7,140.5 449.1,138.6 474.6,142.3 500.0,140.5 525.4,142.3 550.9,142.3 576.3,142.3 601.8,140.5 627.2,140.5 652.7,138.6 678.1,138.6 703.6,138.6 729.0,138.6 754.4,136.8 779.9,138.6 805.3,135.0 830.8,135.0 856.2,125.9 881.7,120.4 907.1,120.4 932.6,120.4 958.0,120.4", "changes": [{"label": "13 Aug 15:34", "short_label": "13 Aug", "collected_at": "2026-08-13T15:34:45.144072+00:00", "score": 58, "delta": 8, "score_change": 0, "score_change_display": "+0", "confidence_change": 0, "article_change": 1, "tone": "positive", "height": 16, "articles": 41, "confidence": 50, "evidence_status": "measured", "evidence_label": "Measured", "score_version": "evidence-v7", "reconstructed": true}, {"label": "12 Aug 23:59", "short_label": "12 Aug", "collected_at": "2026-08-12T23:59:59.999999+00:00", "score": 58, "delta": 8, "score_change": 0, "score_change_display": "+0", "confidence_change": -2, "article_change": 0, "tone": "positive", "height": 16, "articles": 40, "confidence": 50, "evidence_status": "measured", "evidence_label": "Measured", "score_version": "evidence-v7", "reconstructed": true}, {"label": "11 Aug 23:59", "short_label": "11 Aug", "collected_at": "2026-08-11T23:59:59.999999+00:00", "score": 58, "delta": 8, "score_change": 0, "score_change_display": "+0", "confidence_change": 7, "article_change": 7, "tone": "positive", "height": 16, "articles": 40, "confidence": 52, "evidence_status": "measured", "evidence_label": "Measured", "score_version": "evidence-v7", "reconstructed": true}, {"label": "10 Aug 23:59", "short_label": "10 Aug", "collected_at": "2026-08-10T23:59:59.999999+00:00", "score": 58, "delta": 8, "score_change": 3, "score_change_display": "+3", "confidence_change": 2, "article_change": 3, "tone": "positive", "height": 16, "articles": 33, "confidence": 45, "evidence_status": "measured", "evidence_label": "Measured", "score_version": "evidence-v7", "reconstructed": true}, {"label": "09 Aug 23:59", "short_label": "09 Aug", "collected_at": "2026-08-09T23:59:59.999999+00:00", "score": 55, "delta": 5, "score_change": 5, "score_change_display": "+5", "confidence_change": 3, "article_change": 1, "tone": "neutral", "height": 10, "articles": 30, "confidence": 43, "evidence_status": "measured", "evidence_label": "Measured", "score_version": "evidence-v7", "reconstructed": true}, {"label": "08 Aug 23:59", "short_label": "08 Aug", "collected_at": "2026-08-08T23:59:59.999999+00:00", "score": 50, "delta": 0, "score_change": 0, "score_change_display": "+0", "confidence_change": 2, "article_change": 2, "tone": "neutral", "height": 4, "articles": 29, "confidence": 40, "evidence_status": "measured", "evidence_label": "Measured", "score_version": "evidence-v7", "reconstructed": true}, {"label": "07 Aug 23:59", "short_label": "07 Aug", "collected_at": "2026-08-07T23:59:59.999999+00:00", "score": 50, "delta": 0, "score_change": 2, "score_change_display": "+2", "confidence_change": 6, "article_change": 1, "tone": "neutral", "height": 4, "articles": 27, "confidence": 38, "evidence_status": "measured", "evidence_label": "Measured", "score_version": "evidence-v7", "reconstructed": true}, {"label": "05 Aug 23:59", "short_label": "05 Aug", "collected_at": "2026-08-05T23:59:59.999999+00:00", "score": 48, "delta": -2, "score_change": -1, "score_change_display": "-1", "confidence_change": -1, "article_change": -1, "tone": "neutral", "height": 4, "articles": 26, "confidence": 32, "evidence_status": "provisional", "evidence_label": "Provisional", "score_version": "evidence-v7", "reconstructed": true}]}, "disclaimer": "Educational market research only. Not financial, investment, trading, tax, or legal advice."}